Radius Health, Inc. (RADIUS)  
[ADDRESS_1037496], 7th Floor  
[LOCATION_011], MA [ZIP_CODE] [LOCATION_003]  
(617) 551 -4000
Abaloparatide -SC 
CLINICAL STUDY PROTOCOL: BA058 -05-019 
A Randomized, Double -blind, Placebo -controlled, Phase 3 Multicenter Study to Evaluate 
the Safety and Efficacy of Abaloparatide -SC for the Treatment of Men with Osteoporosis  
This study will be conducted according to the protocol and in compliance with Good Clinical Practice, the 
ethical principles stated in the Declaration of Helsinki, and other applicable regulatory requirements.  
Document Type:  Clinical Study Protocol  
EudraCT Number:  2017 -004220 -30  
IND Number:  73,176  
Version Number:  Amendment 6 ( 30 March 2021)  
Development Phase:  3  
Study Site:  Multicenter; international  
Protocol Version History  
Version Number  Version Date  
Original  12 October 2017  
Amendment 1  09 January 2018  
Amendment 2  30 October 2018  
Amendment 3  06 June 2019  
Amendment 4  10 December 2019  
Amendment 5  02 October 2020  
Confidentiality Statement  
The information in this document contains trade secrets and/or commercial information that are privileged 
or confidential and may not be disclosed unless such disclosure is required by [CONTACT_757975]. In any event, persons to whom the inform ation is disclosed must be informed that the 
information is privileged or confidential and may not be further disclosed by [CONTACT_476]. These restrictions on 
disclosure will apply equally to all future information supplied to you which is indicated  
as privileged  or confidential.  NCT#: [STUDY_ID_REMOVED]
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 2 of 81 STATEMENT OF COMPLIA NCE  
The study will be carried out in accordance with Good Clinical Practice (GCP) , as required by 
[CONTACT_757976]  (ICH) GCP E6 (R2)  guidance . 
In addition, I have read the clinical study protocol with the title of : A Randomized, Double -blind, 
Placebo -controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of 
Abaloparatide -SC for the Treatment of Men with Osteoporosis , Amendment 6 dated 30 March 
2021, and agree to the following conditions:  
• To conduct this study in accordance with the design and provisions of this clinical 
study protocol.  
• To await Institutional Review Board/Independent Ethics Committee (IRB/IEC) 
approval  for the protocol and informed consent (IC) before initiating enrollment into 
the study. If approval is suspended or terminated by [CONTACT_1201]/IEC the principal 
investigator [INVESTIGATOR_757949].  
• To ensure that the requirements for obtaining IC are met and to obtain IC from 
subjects before their enrollment into the study.  
• To provide sufficient and accurate financial disclosure and update information if any 
relevant changes occur during the investigation and for 1 year following the 
completion of the study.  
• To collect and record data as required by [CONTACT_743758] 
(CRF).  
• To maintain the confidentiality of all information received or developed in connection 
with this protocol.  
• To conduct this study in accordance with the ICH GCP  guideline, the Declaration of 
Helsinki, and all applicable regulatory requirements.  
• To permit study -related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s) by [CONTACT_20618]/documents.  
• To maintain study document ation for the period of time required.  
• To report all adverse events (AEs) within the specified timeframe to Radius Health, 
Inc. (RADIUS) or their designee.  
• To report all serious AEs/incidents within 24 hours after becoming aware of the event 
to the Contrac t Research Organization and enter the data into the Electronic Data 
Capture system.  
• To adhere to the publication policy of RADIUS Health, Inc. for data collected during 
this study.  
  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-[ADDRESS_1037497] OF FIGURES  ................................ ................................ ................................ ......................... 8 
PROTOCOL SYNOPSIS  ................................ ................................ ................................ .............. 12 
1. INTRODUCTION  ................................ ................................ ................................ ......21 
1.1. Background  ................................ ................................ ................................ ................. 21 
1.1.1.  Disease and  Study Drug Background  ................................ ................................ ......... 21 
1.1.2.  Study Drug Development  ................................ ................................ ........................... 22 
[IP_ADDRESS].  Nonclinical Studies in Male Animals  ................................ ................................ ......... 22 
[IP_ADDRESS].  Clinical Studies  ................................ ................................ ................................ ........... [ADDRESS_1037498] and Disease Characteristics  ................................ ................................ ........... 52 
6.2.5.  Screening Period (Visit 1)  ................................ ................................ .......................... 52 
6.2.6.  Pretreatment Period (Visit 2)  ................................ ................................ ...................... 53 
6.2.7.  Treatment Period  ................................ ................................ ................................ ........ 54 
6.2.8.  Visit 3 (Day 1)  ................................ ................................ ................................ ............ 54 
6.2.9.  Visit 4 (Month 1)  ................................ ................................ ................................ ........ 55 
6.2.10.  Visit 5 (Month 3)  ................................ ................................ ................................ ........ 55 
6.2.11.  Visit 6 (Month 6)  ................................ ................................ ................................ ........ 56 
6.2.12.  Visit 7 (Month 9)  ................................ ................................ ................................ ........ 57 
6.2.13.  Visit 8 (Month 12)/Early Termination Visit  ................................ ............................... 57 
6.2.14.  Visit 9/Safety Follow -up................................ ................................ ............................. 58 
6.2.15.  Unscheduled Visit  ................................ ................................ ................................ .......58 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 6 of 81 6.3. Vital Signs and Physical Examinations  ................................ ................................ ......58 
6.4. 12-Lead Electrocardiogram  ................................ ................................ ........................ 59 
6.5. Laboratory Evaluations  ................................ ................................ ............................... 59 
6.5.1.  Clinical Laboratory Evaluations  ................................ ................................ ................. 59 
6.5.2.  Serum Markers of Bone Metabolism  ................................ ................................ .......... 60 
6.5.3.  Immunogenicity Testing  ................................ ................................ ............................. 61 
6.5.4.  Pharmacokinetic Testing  ................................ ................................ ............................ 61 
6.5.5.  Specimen Preparation, Handling and Storage  ................................ ............................ 61 
6.6. Imaging Procedures  ................................ ................................ ................................ ....61 
6.6.1.  Dual Energy X -ray Absorptiometry  ................................ ................................ ........... 61 
6.6.2.  Quantitative Computed Tomography  ................................ ................................ ......... 62 
6.6.3.  Clinical and Radiologic Evaluation of Fractures  ................................ ........................ 62 
6.7. Discontinuation from the Study  ................................ ................................ .................. 62 
6.7.1.  Withdrawal of Consent  ................................ ................................ ............................... 63 
6.7.2.  Early Study Termination  ................................ ................................ ............................. 63 
7. ADVERSE EVENT AND SE RIOUS ADVERSE EVENT  
DOCUMENTATION  ................................ ................................ ................................ .64 
7.1. Evaluation of Safety  ................................ ................................ ................................ ...64 
7.1.1.  Adverse Event  ................................ ................................ ................................ ............. 64 
7.1.2.  Serio us Adverse Event  ................................ ................................ ................................ 64 
7.1.3.  Recording an Adverse Event  ................................ ................................ ...................... 65 
[IP_ADDRESS].  Serious and Unanticipated Adverse Device Effects for Abaloparatide -SC ................ [ADDRESS_1037499] to Follow -up ................................ ................................ ................................ .......69 
8. STATISTICAL CONSIDER ATIONS  ................................ ................................ .......70 
8.1. Statistical and Analytical Plans  ................................ ................................ .................. 70 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 7 of 81 8.2. Statistical Hypotheses  ................................ ................................ ................................ .70 
8.3. Analysis Datasets  ................................ ................................ ................................ ........ 70 
8.3.1.  Populations for Analysis  ................................ ................................ ............................. 70 
8.4. Description of Statistical Methods  ................................ ................................ .............. 70 
8.4.1.  General Approach  ................................ ................................ ................................ .......70 
8.4.2.  Analysis of the Primary Efficacy Endpoint(s)  ................................ ............................ 70 
8.4.3.  Analysis of Secondary Endpoint(s)  ................................ ................................ ............ 71 
8.4.4.  Pharmacokinetic Analyses  ................................ ................................ .......................... 73 
8.4.5.  Safety Analyses  ................................ ................................ ................................ .......... 73 
8.4.6.  Adherence and Retention Analyses  ................................ ................................ ............ 74 
8.4.7.  Baseline Descriptive Statistics  ................................ ................................ .................... 74 
8.4.8.  Interim Analyses  ................................ ................................ ................................ ......... 75 
8.4.9.  Additional Subgroup Analyses  ................................ ................................ ................... 75 
8.4.10.  Multiple Comparison/Multiplicity  ................................ ................................ .............. 75 
8.4.11.  Tabulation of Individual Response Data  ................................ ................................ ....75 
8.4.12.  Exploratory Analyses  ................................ ................................ ................................ ..75 
8.5. Sample Size Calculation  ................................ ................................ ............................. 75 
8.6. Measures to Minimize Bias  ................................ ................................ ........................ 75 
8.7. Enrollment/Randomization/Masking Procedures  ................................ ....................... [ADDRESS_1037500] OF TABLES  
Table  1: Summary of PK Data in Subjects Treated with Abaloparatide -SC 80 µg 
(Pooled Data#) ................................ ................................ ................................ ............. 26 
Table  2: Pooled Treatment -Emergent Adverse Events – Differences Between Male 
and Female Subjects in Phase 1 Studies (BA05805 -010, BA05805 -010, 
BA05805 -011, BA [ZIP_CODE] -012, and BA05805 -014) *  ................................ ................. 29 
Table  3: Schedule of Assessments and Procedures  ................................ ................................ ..48 
Table  4: Schedule for Pharmacokinetic Sample Collections  ................................ .................... 51 
Table  5: Clinical Laboratory Tests  ................................ ................................ ........................... [ADDRESS_1037501] OF FIGURES  
Figure 1:  L4 Vertebra l Body BMD after 4 Weeks of Treatment in Male Rats  .......................... 23 
Figure  2: PK Concentration over Time in Subjects Treated with Abaloparatide -SC 
80 µg (Pooled Data#) ................................ ................................ ................................ ..27 
Figure  3: Study BA058 -05-012 – Mean (95% CI) Change from Baseline in Serum 
Calcium over Time by [CONTACT_757977] A baloparatide 80 µg Treatment (Safety 
Population)  ................................ ................................ ................................ .................. 28 
Figure 4:  Study BA058 -05-019 Design  ................................ ................................ ..................... 33 
Figure  5: Treatment Algorithm in Subjects Who Develop Hypercalcemia  ............................... [ADDRESS_1037502]   Aspartate aminotransferase  
AUC   Area under the plasma concentration -time curve  
AUC 0–∞ 
 Area under the plasma concentration -time curve from time zero 
to infinity  
AUC last  
 Area under the plasma concentration -time curve from time zero 
to the time of the last quantifiable concentration  
BMD   Bone mineral density  
BMI   Body mass index  
BP  Blood pressure  
bpm  Beats per minute  
BSAP   Bone -specific alkaline phosphatase  
BUN   Blood urea nitrogen  
BVF   Bone volume fraction  
cAMP   Cyclic  adenosine monophosphate  
Cmax  Maximum plasma concentration  
COVID -[ADDRESS_1037503]  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 10 of 81 Abbreviation   Term  
HIV  Human immunodeficiency virus  
IB  Investigator's Brochure  
IC  Informed consent  
ICF  Informed consent form  
ICH  International Council for Harmonisation  
IEC  Independent Ethics Committee  
IRB  Institutional Review Board  
IRT  Interactive response technology  
ITT  Intent ion-to-treat 
IUD  Intrauterine device  
IV  Intravenous  
LDH   Lactate dehydrogenase  
LLN   Lower limit of normal  
LOCF   Last observation carried forward  
MedDRA   Medical Dictionary for Regulatory Activities  
mmHg   Millimeter of mercury  
MMRM   Mixed Model for Repeated Measures  
ONJ  Osteonecrosis of the jaw  
ORX   Orchidectomized  
PI  [INVESTIGATOR_168834](s)  
PMM   Pattern -mixture model  
PP  Per-Protocol  
PT  Prothrombin time  
PTH   Parathyroid hormone  
PTHR [ADDRESS_1037504] operating procedure  
s-PI[INVESTIGATOR_757950] I N -terminal propeptide  
S[LOCATION_003]R   Suspected unexpected serious adverse reaction  
t1/[ADDRESS_1037505]   Upper limit of normal  
US  [LOCATION_002]  
vBMD   Volumetric bone mineral density  
WHO   World Health Organization  
 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 12 of 81 PROTOCOL SYNOPSIS  
Title: A Randomized, Double -blind, Placebo -controlled, Phase 3 Multicenter Study to Evaluate 
the Safety and Efficacy of Abaloparatide -SC for the Treatment of Men with Osteoporosis  
Protocol Number:  BA058 -05-[ADDRESS_1037506] Drug:  Abaloparatide 80 µg for subcutaneous injection  
Study Objectives and Endpoints  
Objective:  The primary objective of this prospective controlled study is to evaluate the efficacy 
and the safety of abaloparatide -subcutaneous (SC) 80 µg per day compared to placebo in men 
with osteoporosis.  
Endpoints  
The primary efficacy endpoint is the percent change from baseline in lumbar spi[INVESTIGATOR_757951] (BMD) at 12  months.  
The key secondary efficacy endpoints are:  
• Percent change from baseline in total hip BMD at 12 months  
• Percent change from baseline in femoral neck BMD at 12 months  
Additional secondary efficacy endpoints are:  
• Percent change from baseline in : 
− Lumbar  spi[INVESTIGATOR_531859] 3 and 6 months  
− Total hip BMD at 3 and 6 months  
− Femoral neck BMD at 3 and 6 months  
− Ultra -distal radius BMD at 3, 6, and 12 months  
− Distal one -third radius BMD at 3, 6, and 12 months  
• Log ratio of post -baseline over baseline in : 
− Serum procollagen  type I N -terminal propeptide (s -PI[INVESTIGATOR_680]) at 1, 3, 6, and 12 
months  
− Serum carboxy -terminal cross -linking telopeptide of type I collagen (s -CTX) at 1, 
3, 6, and 12  months  
• Proportion of subjects experiencing BMD gains from baseline of >  0%, >  3%, and 
> 6% at th e lumbar spi[INVESTIGATOR_050], femoral neck, and total hip at 3, 6, and 12 months  
• Incidence of new clinical fractures at 12 months  
• Proportion of subjects converting from the categories of osteoporosis to osteopenia or 
to normal at 12  months, where:  
− Osteoporosis is defined as lumbar spi[INVESTIGATOR_757952] T -score ≤  -2.5.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 13 of 81 − Osteopenia is defined as one of the following:  
o Lumbar spi[INVESTIGATOR_050] > -2.5 and total hip BMD T -score > -2.5 and < -1.0  
o Lumbar spi[INVESTIGATOR_050] > -2.5 and < -1.0 and total hip BMD T -score > -2.5 
− Normal is defined as l umbar spi[INVESTIGATOR_757953] T -score ≥ -1.0. 
• The percent change in total hip and femoral neck volumetric BMD (vBMD) as 
measured by [CONTACT_621948] (QCT) from baseline to [ADDRESS_1037507] will be 
performed in a subset of subjects at a selected number of stud y sites.  
For those subjects who consent to pharmacokinetic ( PK) sample collection, the PK endpoints 
are: 
• The plasma concentration of abaloparatide based on sparse PK sampling at the 
following visits:  
− Month 6: postdose PK samples collected 45 minutes ( ±15 minutes) and 2.5  hours 
(±0.5 hour) after abaloparatide -SC injection  
− Month 9: postdose PK samples collected 20 minutes ( ±10 minutes) and 4  hours 
(±0.5 hour) after abaloparatide -SC injection  
− Month 12: a predose sample and a postdose sample collected 1.5 hour s 
(±0.5 hour) after abaloparatide -SC injection  
The safety endpoints are:  
• Overall safety and tolerability of abaloparatide -SC in men with osteoporosis as 
assessed by [CONTACT_20721] (AE), vital signs, electrocardiograms (ECGs), laboratory 
tests of chemistry and hematology, urinalyses, local tolerance, and presence of 
antibodies  
Subgroup analyses (e.g., age, geography, Fracture Risk Assessment, FRAX [if applicable], prior 
fracture, and baseline BMD, s -PI[INVESTIGATOR_680], testosterone, and estradiol levels) may be performed and 
will be described in the Statistical Analysis Plan.  
Study Population  
Men aged [ADDRESS_1037508] is a healthy ambulatory male from 40 to 85 years of age (inclusive) with 
primary osteoporosis or osteoporosis associated with hypogonadism.  
2. The subject has a BMD T -score (based on the male reference range as assessed by [CONTACT_54644]) of:  
a. ≤ -2.5 at the lumbar spi[INVESTIGATOR_050] (L1 –L4) or hip (femoral neck or t otal hip) by [CONTACT_11323] 
X-ray absorptiometry (DXA); or  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 14 of 81 b. ≤ -1.5 and with radiologic evidence of vertebral fracture or a documented (radiograph 
films or report) history of low -trauma nonvertebral fracture sustained in the past [ADDRESS_1037509] a BMD T -score ≤ -2.[ADDRESS_1037510] is in good general health as determined by [CONTACT_723] (including vital signs) and is without evidence of a clinica lly significant 
abnormality in the opi[INVESTIGATOR_689], or none for which there is a reasonable 
chance of interfering with the subject’s health and/or medical treatment during the study. 
The subject has a body mass index (BMI) of 18.[ADDRESS_1037511]’s height and weight. In the case where a subject’s height cannot be 
adequately assessed (e.g., due to vertebral compression fractures or scoliosis), the subject’s 
historical height (as documented in the subject’s me dical record) will be used to derive the 
BMI.   
4. Hypogonadal subjects whose doses of androgens have been stable for at least [ADDRESS_1037512] has serum calcium (albumin -correct ed), parathyroid hormone (PTH), serum 
phosphorus and alkaline phosphatase, and thyroid stimulating hormone (TSH) values all 
within the normal range during the Screening Period. Any subject with an elevated 
alkaline phosphatase value and who meets all other  entry criteria must have a normal 
bone -specific alkaline phosphatase to be enrolled. Any subject with a TSH value outside 
of the normal range must have central laboratory reported T3 and free T4 values within 
the normal ranges to be enrolled.  
6. The subject has serum 25 -hydroxyvitamin D values ≥  20 ng/mL and within the normal 
range. Subjects with serum 25 -hydroxyvitamin D levels <  20 ng/ml may be treated with 
vitamin D and retested once during the Screening Period.  
7. The subject’s systolic blood pressure is ≥ 1 00 and ≤  155 mmHg, diastolic blood pressure 
is ≥ 40 and ≤  95 mmHg, and heart rate is ≥  45 and ≤  100 bpm (taken sitting or supi[INVESTIGATOR_050]). 
Any recorded values outside of these ranges and assessed by [CONTACT_757978] d with the Medical Monitor and Sponsor for 
approval prior to enrollment.  
8. The subject has no clinically significant abnormality of serum hemoglobin, hematocrit, 
white blood cells and platelets, or usual serum biochemistry: electrolytes, renal function, 
liver function and serum proteins that might be expected to interfere with the subject’s 
health and/or medical treatment during the study.  
9. In subjects who have partners of childbearing potential, the subject and his partner should 
abstain from sexual intercour se, or use highly effective contraceptive measures (e.g., oral 
contraceptive and condom, intrauterine device [IUD] and condom, or diaphragm with 
spermicide and condoms; other forms of contraception must be approved by [CONTACT_22955]) when engaging in sexual intercourse throughout the study, and for at least [ADDRESS_1037513] has read, understood, and signed the written informed consent form.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 15 of 81 Exclusion Criteria  
General exclusion criteria:  
1. Presence of abnormalities  of the lumbar spi[INVESTIGATOR_757954], defined as having at least 2 radiologically evaluable vertebrae within L1 –L4 as 
assessed by [CONTACT_757979].  
Anatomically abnormal vertebrae are excluded if:  
• They are clearly abn ormal and non -assessable within the resolution of the system; or  
• There is a more than 1.0 T -score difference between the vertebra in question and 
adjacent vertebrae.  
2. A BMD T -score of ≤ -3.[ADDRESS_1037514] undergone bilateral hip replacement 
(unilateral hip replacement is acceptable).  
4. Fragility fracture within the past 12 months.  
5. History of severe vertebral fracture or > 2 moderate vertebral fracture s. 
6. History of bone disorders (e.g., Paget’s disease) other than osteoporosis.  
7. Subjects with clinical signs of hypogonadism present at screening who plan to initiate 
testosterone replacement.  
8. History of prior external beam or implant radiation therapy invol ving the skeleton, other 
than radioiodine.  
9. History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular, 
gastrointestinal, endocrine, central nervous system, hematologic or metabolic diseases, or 
immunologic, emotional and/or psychia tric disturbances to a degree that would interfere 
with the interpretation of study data or compromise the safety of the subject.  
10. History of Cushing’s disease, growth hormone deficiency or excess, hyperthyroidism, 
hypo - or hyperparathyroidism or malabsorpt ive syndromes within the past year.  
11. History of significantly impaired renal function (serum creatinine >  177 μmol/L or 
> 2.0 mg/dL). If the serum creatinine is >  1.5 and ≤ 2.0 mg/dL, the calculated creatinine 
clearance (Cockcroft -Gault) must be ≥  37 mL/min.  
12. History of any cancer within the past 5 years (other than basal cell or squamous cancer of 
the skin).  
13. History of osteosarcoma at any time.  
14. Subjects with hereditary disorders predisposing to osteosarcoma.  
15. History of nephrolithiasis or urolithiasis w ithin the past 5 years.  
16. Subjects known to be positive for Hepatitis B, Hepatitis C, human immunodeficiency 
virus (HIV) -1 or HIV -2. Testing is not required in the absence of clinical signs and 
symptoms suggestive of HIV infection or acute or chronic hepatit is. 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 16 of 81 Medication -related exclusion criteria:  
17. Known history of hypersensitivity to any of the test materials or related compounds.  
18. Prior treatment with PTH - or parathyroid hormone related protein (PTHrP) -derived 
drugs, or bone anabolic drugs including abalopa ratide, teriparatide, or PTH(1 -84). 
19. Prior treatment with intravenous (IV) bisphosphonates at any time or oral 
bisphosphonates within the past 3 years. Subjects who had received a short course of oral 
bisphosphonate therapy (3 months or less) may be enrolle d as long as the treatment 
occurred [ADDRESS_1037515] 5 years or prior treatment with gallium 
nitrate or other bone -acting investigational agents at any time. Limited use of gallium 
citrate/nitrate for diagnostic purposes (i.e., a gallium scan) is not exclusionary.  
21. Prior treatment with calcitonin or tibolone in the past [ADDRESS_1037516] vitamin D metabolism (phenobarbital, 
phenytoin, carbamazepi[INVESTIGATOR_050], or primidone) or with chronic heparin within the 6 months 
prior to the Screening Period.  
24. Treatment with anabolic steroids or calcineurin inhibitors (cyclosporin, tacrolimus) 
within the past 90  days.  
25. Daily treatment with oral, intranasal, or inhaled corticosteroids within the 12  months 
prior to the Screening Period. Occasional use of all corticosteroids (for seasonal allergies 
or asthma) is not exclusionary.  
26. Exposure to an investigational drug within the 12 months prior to the Screening Period.  
Lifestyle -related exclusion criteria:  
27. Abnormal nutritional status (as assessed by [CONTACT_737]), vitamin D intake of 
≥ 4,000  IU/day or vitamin A intake of ≥ 10,000 IU/day. Short term use of high doses of 
vitamin  D to increase endogenous vitamin D levels for study entry is not exclusionary.  
28. Subject is known to consume >  2 alcoholic drinks per day, to use illegal drugs, or to 
abuse tobacco or marijuana (medicinally or recreationally where legal) within [ADDRESS_1037517] of a Screening Period (up to 2 months), a Pretreatment Period (1  week), and a Treatment 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 17 of 81 Period (12 months) with a final visit [ADDRESS_1037518] dose of study medication (Follow -up 
Visit). Eligible subjects will be randomized, on a 2:[ADDRESS_1037519] of 
abaloparatide on lumbar spi[INVESTIGATOR_757955] -related endpoints. Both groups of 
subjects will undergo protocol -specified procedures (Sche dule of Assessments and Procedures, 
Table  3) including BMD and fracture assessments. The study design is presented in the figure 
below.  
Protocol BA058 -05-[ADDRESS_1037520] dose of study 
medication. For the purposes of this study 1 month is equal to 30 days.  
Treatments Administered  
Eligible subjects will be randomly allocated, using a 2:[ADDRESS_1037521] treatment in the case of medical emergency, an d with exception of Sponsor 
pharmacovigilance and/or regulatory personnel as needed for suspected unexpected serious 
adverse reaction (S[LOCATION_003]R) reporting purposes. All subjects will be provided calcium and vitamin 
D to ensure that their daily intake is in th e range of calcium 500 –1000  mg/day and vitamin D 
400-800 IU/day, or a dose determined by [CONTACT_757980], according to the subject’s need.  
Procedures and Assessments  
Refer to the Schedule of Events for full detail s about the procedures and assessments required at 
each study visit.  

Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 18 of 81 During the Screening Period, informed consent will be obtained, eligibility for study entry 
assessed, and screening evaluations performed, including baseline lumbar and thoracic spi[INVESTIGATOR_757956], BMD assessments by [CONTACT_11324], serum total testosterone, sex hormone binding 
globulin, and baseline laboratory tests.  
• Subjects whose laboratory tests do not fall within the specified ranges as detailed in 
the inclusion/exclusion criteria may have the sa mples redrawn and the tests repeated 
once during the Screening Period. If upon retesting, the values fall within the 
inclusion/exclusion criteria, the subject may enter the study.  
• Subjects who do not meet the vitamin D entry criterion (their 25 -hydroxyvita min D is 
less than 20 ng/ml) may receive vitamin D supplementation and be retested once 
during the Screening Period as may subjects with minor elevations of PTH. All 
subjects enrolled following retesting must have safety labs within 30 days of 
randomizatio n (Day  1). 
Following these evaluations, eligible subjects will enter the Pretreatment Period of the study and 
will be given daily calcium and vitamin D supplements, which will continue until the end of the 
Treatment Period. Subjects will also receive train ing in the use of the injector pen for self -
administration.  
At Day 1, the subject will have baseline assessments including bone turnover markers, 
immunogenicity testing, DXA of the wrist, and QCT measurement at the hip (at a subset of 
sites).  
During the Treatment Period, subjects will self -administer a single subcutaneous dose of the 
randomly assigned study medication once a day. Subjects will have clinic visits for study -related 
protocol procedures at Day 1, Month 1, Month 3, Month 6, Month 9,  and Month 12. Study 
procedures will include the measurement of BMD by [CONTACT_757981]. At each visit, clinical fractures will also be assessed. Serum 
samples for evaluation of calcium after study drug  administration and immunogenicity testing 
will be drawn at specified visits during the Treatment Period.  
Statistical Considerations  
The primary population for efficacy analyses will be the Intention -to-Treat (ITT) Population , 
defined as all subjects rand omized into this study. The primary population for safety analyses 
will be the Safety Population, defined as all subjects who received at least one dose of study 
medication. The Per -Protocol Population  will include  all ITT subjects who did not have any 
significant protocol deviations and will be used for supportive analyses.  
Sample Size  
A study sample size of 225 subjects (150 in the abaloparatide -SC group and 75 in the placebo 
group) will provide at least 99% power to detect a mean difference of 6.5% in th e percentage 
change from baseline in lumbar spi[INVESTIGATOR_531859] [ADDRESS_1037522] deviation (SD) of 6.0% and a 
drop-out rate of 10%.  
For the key secondary endpoints, this total sample size of [ADDRESS_1037523] 96% power to 
detect a 2.2% mean difference (SD  = 3.5%) of percent change in total hip BMD at 12 months 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 19 of 81 and 80% power to detect a 2.0% mean difference (SD  = 4.1%) of percent change in femoral neck 
BMD at [ADDRESS_1037524] 
statistics. To claim statistical significance at the 2 -sided level of 1%, the following 3 fixed -
sequence tests will be performed in sequential order. At any step of the sequential testing, if the 
treatment difference is not statistically significant at the 1% level then all the subsequent 
comparisons following the fixed sequence cannot be claimed statistically significa nt. 
1. Percent change from baseline in BMD at the lumbar spi[INVESTIGATOR_16717] 12 months  
2. Percent change from baseline in BMD at the total hip at 12 months  
3. Percent change from baseline in BMD at the femoral neck at 12 months  
P-values for treatment comparisons of all other efficacy endpoints will be generated to support 
the study findings without any adjustments for multiplicity.  
For the analysis of BMD data, the primary analysis will be based on a pattern -mixture model 
(PMM) analysis with multiple imputation using the wash -out imputation method. This method 
uses sequential regression and wash -out imputation methodology to impute missing values after 
a subject’s discontinuation from the study. The missing primary endpoint values for subjects in 
the abaloparatide -SC group will be imputed with the observed baseline and data from the 
placebo group; no intermediate values from the abaloparatide -SC group  will be used in the 
imputation for the abaloparatide -SC group. For subjects in the placebo group, intermediate 
observed values fr om the completers in the placebo group will be used while imputing missing 
values during the 12 -month Treatment Period . The PROC MI methodology for imputation of 
monotone missing data patterns will be used to impute the outcome variables at consecutive 
visits in a sequential (chain) manner. Each of these imputed datasets will be analyzed using 
analysis of covariance (ANCOVA) with treatment and DXA instrument manufacturer as fixed 
effects and the baseline lumbar spi[INVESTIGATOR_757957] a covariate. Results from all imp uted datasets will 
be combined using PROC MIANALYZE for overall statistical inference. The statistical tests will 
be 2-sided comparing abaloparatide -SC to placebo; 99% CIs will be presented together with the 
estimated p -values.  
Analysis of bone turnover ma rkers, s -PI[INVESTIGATOR_686] s -CTX, will be based on the ratio of the post -
baseline value relative to the baseline value at each visit. The transformation of the log e ratio of 
post-baseline versus baseline value will be used to normalize the distrib utions of the s -PI[INVESTIGATOR_686] 
s-CTX parameters. The analysis comparing abaloparatide -SC with placebo will use a PMM 
analysis with multiple imputation using the wash -out imputation method , as described for BMD.  
Safety Analysis  
Safety analysis will be analyzed descriptively and will include the following parameters:  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 20 of 81 • Treatment -emergent AEs (TEAEs)  
• Changes in vital signs (including orthostatic blood pressure [BP]), ECGs, and 
laboratory (hematology, serum chemistry, and urinalysis) tests  
• Investigator and subject assessment of local tolerance  
• Presence of antibodies  
All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA).  
Safety  
Recent health status will be obtained, the diary reviewed, and AEs collected at each visit and 
vital signs will be performed at e ach clinic visit. Laboratory assessments of chemistry and 
hematology, and urinalyses will be obtained at screening, and at Month 1, Month 6, and 
Month  12. A final visit will take place [ADDRESS_1037525] who demonstrates decreases in BMD ≥  7% from baseline of this study at the lumbar 
spi[INVESTIGATOR_757958], if confirmed, will be notified by [CONTACT_3786], and be withdrawn from the study. Subjects sustaining a radiologically  confirmed 
incident vertebral or nonvertebral fragility fracture will be informed of the finding and will be 
counseled as to treatment options and may discontinue or choose to remain on the study. Should 
a subject who experiences an incident clinical verte bral or nonvertebral fragility fracture choose 
to remain in the study, he will be asked to sign an additional informed consent form explaining 
the potential risks and benefits of remaining in the study.  
Duration of Subject Participation:  
Participation will  be up to 16 months (12 months total treatment duration).  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 21 of 81 1. INTRODUCTION  
1.1. Background  
Human  parathyroid hormone ( PTH ) is a  naturally  occurring 84 amino  acid hormone and  is 
primarily a  regulator of calcium  homeostasis  (Mannstadt  et al, 1999 ). PTH acts  directly on bone 
to increase  calcium  resorption,  on the gastrointestinal  system  to increase  calcium  absorption,  and 
on the kidney to increase calcium  reabsorption  and 1,25-dihydroxyvitamin  D production.  In turn, 
PTH levels  are tightly  regulated  by [CONTACT_757982]  D levels.  When given  intermittently at 
low doses,  PTH  has a well-documented  anabolic  effect  on bone,  and can increase  bone mineral 
density ( BMD) in a number of intact animal  models  and in osteoporotic subjects  (Dempster et al, 
1993 ). 
Abaloparatide (marketed as TYMLOS® in the Uni ted States [US]) is a novel, synthetic, 34  amino 
acid peptide designed to be a potent and selective activator of the PTH/PTH -related protein 
(PTHrP) type 1 rece ptor (PTHR 1) signaling pathway with 41% homology to PTH[1 –34]) and 
76% homology to human PTHrP[1 –34]. Abaloparatide is differentiated from PTH and PTHrP 
ligands based on its high affinity and >  1,000 -fold greater selectivity for the G  protein -coupled 
(RG) vs the non -G protein -coupled (R0) conformation of PTHR 1 (Hattersley et al, 2016 ). 
Differential PTHR 1-RG binding with abaloparatide results in potent and transient intracellular 
cyclic adenosine monophosphate (cAMP) signaling. In nonclinical studies, the transient PTHR [ADDRESS_1037526] on bone 
resorption ( Makino et al, 2015 ). Thus, abaloparatide was developed with the expectation that it 
would be effective at increasing BMD and reducing fracture in individuals with osteoporosis, but 
with a limited effect on bon e resorption and a reduced risk of hypercalcemia.  
1.1.1.  Disease and Study Drug Background  
Osteoporosis is a systemic skeletal disease characterized by [CONTACT_757983] d risk 
of fractures ( Rizzoli et al, 2001 ). This disease is characterized by [CONTACT_648784]. The 
fractures associated with the greatest morbidity and mortality, as well as economic burden to 
society, together make up th e clinically significant and medically relevant group termed major 
osteoporotic fractures. In the US, there are an estimated 2 million osteoporotic fractures annually 
(Litwic et al, 2014 ). The number of osteoporotic fractures is projected to increase in both men 
and women by [CONTACT_726] 3 -fold over the next 50 years as a result of the aging population ( WHO 
2007 ). 
Although osteoporosis predominantly affects postmenopausal women, approximately 20% of 
men over the age of [ADDRESS_1037527] of treatment and rehabilitation for fractures in men in the US was $4.1 billion 
and this is projected to rise to $6.8 billion in 2025 ( IOF 2014 ). Most men experience bone loss 
with aging and low BMD is frequent in older men and a risk factor for fracture. Many different 
risk factors may contribute to bone loss and fracture risk in men, including most importan tly 
hypogonadism, glucocorticoids, and excessive alcohol use ( Ebeling 2008 ). Additionally, some 
men develop osteoporosis without apparent cause, so -called idiopathic osteoporosis ( Khosla 
2008 ).  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 22 of 81 Bone remodeling occurs through the action of osteoclasts, which are involved in the resorption 
of bone followed by [CONTACT_727]. In addition to continued use of 
calcium and vitamin D, the current therapeutic approach to the trea tment of osteoporosis through 
inhibition of bone resorption includes agents such as bisphosphonates ( Rosen 2005 ) or 
monoclonal antibody denosumab, that inhibits the action of osteoclasts by [CONTACT_757984] -B (RANK) ligand. An alternative approach has been to tip the 
balance between osteoblastic bone formation and osteoclastic resorption through the use of 
parathyroid hormone receptor modulation using ter iparatide (rhPTH[1 –34]).  
Until recently, teriparatide has been the only approved osteoporosis treatment in which the major 
mode of action is stimulation of bone formation (anabolic) rather than suppression of bone 
resorption. The efficacy of teriparatide h as important limitations related to its delayed and 
modest effects on increasing BMD at the total hip and femoral neck, and on decreasing BMD at 
the distal one-third  radius. The increase in cortical porosity that can occur may result in 
maladaptive effects  on cortical bone microarchitecture ( Bilezikian 2007 ). Abaloparatide has been 
evaluated in a number of nonclinical and clinical studies for its potential as a novel treatment for 
osteoporosis. Based on the biology of the P TH [ADDRESS_1037528] also been approved for the treatment of osteoporosis in men or to increase bone mass in 
men with osteoporosis.  
1.1.2.  Study Drug Development  
[IP_ADDRESS].  Nonclinical Studies in Male Animals  
Abaloparatide was tested in a non -Good Laboratory Practice (GLP) pharmacology study 
(16RADL120) using a male rat castration (orchidectomized [ORX]) model of osteoporosis. Male 
rats underwent ORX or sham surgery at approximately 3 months of age and following a 4 -week 
bone depletion period. Treatment was then initiated with either abaloparatide (20  μg/kg/d, n = 8) 
or vehicle (n = 8) once daily for an additional 4 -weeks. After 8 we eks of androgen deficiency, 
the ORX group had 13% lower L4 BMD and 17% lower trabecular bone volume fraction (BVF), 
compared with sham controls. After 4 weeks of treatment, the abaloparatide treated group had a 
17% greater L4 BMD, 50% greater BVF, and 33% greater trabecular thickness compared with 
ORX controls (all p  < 0.0001),  Figure 1. Trabecular bone pattern factor was 39% lower 
compared with ORX con trols (p  < 0.05), suggesting a more organized and better -connected 
trabecular architecture. The abaloparatide group also had 24%  greater BVF and 29% greater 
trabecular thickness, compared with sham controls (both p  < 0.01). These data demonstrate that 
abaloparatide reversed vertebral BMD loss and restored trabecular microarchitectural 
deterioration in ORX rats by [CONTACT_757985].  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 23 of 81 Figure 1: L4 Vertebral Body BMD after 4 Weeks of Treatment in Male Rats  
 
Two rodent GLP nonclinical studies were completed evaluating abaloparatide effects on male 
reproduction following repeated subcutaneous administration. A 4 -week repeat -dose toxicology 
study with male fertility assessment (BA058 -114) and a definitive male f ertility study with an 
early embryonic development component (SBL062 -288) were performed. In both studies, 
Abaloparatide failed to produce adverse effects in male fertility indices, fecundity, early 
embryonic development, and spermatogenesis at exposures u p to 128 -fold human exposure 
(animal: human exposure multiple) based on a human area under the concentration -time curve 
(AUC) of 1546 pg*hr/mL from Study BA058 -05-001B and AUC from the rat 28 -day repeat -
dose toxicology Study BA058 -114. 
Abaloparatide was te sted in repeat -dose toxicity studies in male rats up to 70  μg/kg for up to 
26 weeks (BA058 -114, BA058 -115 and 7801 -124), and in male monkeys at 10  μg/kg for up to 
39 weeks (BA058 -119 and 7801 -125). The conclusions from the repeat -dose toxicity studies 
were  consistent with a primary pharmacology of abaloparatide associated with a new bone 
formation in male animals. There were no significant differences in safety, tolerability or 
histopathological findings between male and female animals noted in these studie s. These 
nonclinical results are consistent with abaloparatide having positive bone anabolic effect in male 
animals.  
[IP_ADDRESS].  Clinical Studies  
There are 19 completed and ongoing clinical studies which comprise the abaloparatide -
subcutaneous (SC) and abaloparatide -solid microstructured transdermal system (sMTS) clinical 
development program. The abaloparatide -SC clinical trial program consists of 11 clinical trials, 
including a large pi[INVESTIGATOR_9205] 3 study (BA058 -05-003) followed by [CONTACT_3440] -label extension 
(Study BA058 -05-005) and Phase 2 studies in postmenopausal women with osteoporosis 
(abaloparatide -SC Studies BA058 -05-002 and BA058 -05-002 extension as well as 
BA058 -05-007, an abaloparatide -sMTS study in which abaloparatide -SC at a dose of 80  µg was 
[IP_ADDRESS].[IP_ADDRESS].58
SHAM ORX ORX + ABLgHA/cc
Day 28
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 24 of 81 used as the activ e comparator) and Phase 1 studies in healthy postmenopausal women, healthy 
male and female subjects, and subjects with renal impairment.  
In the pi[INVESTIGATOR_9205] 3 study (BA058 -05-003, the ACTIVE trial), 2,463 postmenopausal women 
were randomized to receive da ily 80 µg abaloparatide -SC (n = 824), placebo (n = 821), or 
teriparatide 20 µg (n = 818) (rhPTH 1 -34) for 18 months. In this trial, abaloparatide -SC and 
teriparatide significantly reduced the risk of new morphometric vertebral fractures, by 86% and 
80%, re spectively, compared to placebo. Abaloparatide -SC significantly reduced nonvertebral, 
major osteoporotic and clinical fractures compared to placebo. Compared to teriparatide, 
abaloparatide significantly reduced major osteoporotic fractures. The Kaplan -Meie r plots 
indicate an early and sustained fracture risk reduction of nonvertebral, major osteoporotic and 
clinical fractures with abaloparatide -SC treatment. Abaloparatide -SC has an acceptable safety 
profile, and consistent with reduced abaloparatide -SC-medi ated calcium mobilization, the rates 
of hypercalcemia were lower in the abaloparatide -SC group compared to the teriparatide group.  
In the ACTIVExtend trial (BA058 -05-005), subjects who were in the abaloparatide -SC or 
placebo arms were transitioned to oral alendronate [ADDRESS_1037529] statistically 
significant reductions in nonvertebral, major osteoporotic, and clinical fractures when compared 
to subjects who previously received 18 months of placebo followed by 6 months of alendronate. 
These results validate the osteoporosis treatment paradigm of build (with an anabolic agent), and 
then maintain and consolidate gains (with an antiresorptive agent).  
Abaloparatide -SC demonstrated an increase in BMD at the lumbar  spi[INVESTIGATOR_050], total hip, femoral neck, 
and ultra -distal radius in osteoporosis subjects, consistent with the fracture risk reduction. The 
results from the ACTIVE trial and the first 6 months of the ACTIVExtend trial, together with the 
entire data set from the ab aloparatide -SC development program, support the safety and efficacy 
of abaloparatide -SC for the reduction of fractures in postmenopausal women with osteoporosis.  
At the 43 -month timepoint, the previous abaloparatide -SC treated subjects, who received up to 
2 years of treatment  with alendronate, had a significant 84% relative risk reduction (p  < 0.0001) in 
the incidence of new vertebral fractures compared with women who received placebo followed by 
[CONTACT_757986] 2 years. They also demonstrated a 39% r isk reduction in nonvertebral 
fractures (p = 0.038), a 34% risk reduction in clinical fractures (p = 0.045) and a 50% risk 
reduction in major osteoporotic fractures (p = 0.011) compared with women who received placebo 
followed by [CONTACT_158909].  
The adverse e vents (AEs) were comparable between  abaloparatide -SC treated subjects and the 
previous placebo group. The incidences of cardiovascular AEs including serious adverse events 
(SAEs) were similar between groups. There have been no cases of osteonecrosis of the  jaw (ONJ) 
or atypi[INVESTIGATOR_147167] (AFF) in the entire abaloparatide -SC development program.  
Overall, the clinical results of abaloparatide -SC-mediated early vertebral and nonvertebral 
fracture risk reduction and increases in BMD are consistent with t he known anabolic mechanism 
of action, changes in bone turnover markers and nonclinical results.  
For the most up -to-date information on clinical studies with abaloparatide, refer to the 
abaloparatide Investigator’s Brochure (IB).   
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-[ADDRESS_1037530] of abaloparatide -SC in men is indeed a clinical priority. The present 
study seeks to provide that confirm ation, in order for abaloparatide -SC to be made available to 
men with osteoporosis and whose clinical need remains unmet by [CONTACT_757987][INVESTIGATOR_014].  
1.3. Dose Rationale  
The approved dose of abaloparatide -SC in the US for the treatment of postmenopausal wo men at 
a risk for fracture is 80 µg per day, this is also the proposed dose in the European Union (EU). 
While the long -term treatment of men with abaloparatide -SC has not been evaluated, Phase [ADDRESS_1037531] been conducted to evaluate pharmacokinetics foll owing a single administration of 
abaloparatide -SC, at a dose of 80 µg in both male and female subjects, the proposed dose 
selected for the present study.  
To provide a comparison of pharmacokinetics (PK) and safety for male and female subjects, the 
data fro m 3 recent Phase 1 clinical trials were pooled (BA058 -05-010 was a 
bioavailability/maximum tolerated dose study, BA058 -05-011 was a study in subjects with 
varying degrees of renal disease, BA058 -05-012 was a study to determine the effects of 
abaloparatide -SC on total depolarization and repolarization time / total depolarization and 
repolarization time corrected with heart rate (QT/QTc) and BA058 -05-014 was a study done to 
provide initial evaluation of the bioequivalence of abaloparatide administered subcuta neously 
from 2 similar pen injectors to healthy male and female subjects). Summary PK data are 
presented in  Table  1. The 90% CI s for the ratio of AUC and for the ratio of maximum serum 
concentration (C max) between males and females were generated based on an analysis of variance 
(ANOVA) model with sex as fixed effect. Maximal time (t max) values were compared using a t -
test. These results show that there wer e no differences in the systemic exposure of abaloparatide -
SC between male and female subjects following a single administration of abaloparatide -SC at a 
dose of 80 µg.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 26 of 81 Table  1: Summary of PK Data in Subjects Treated wi th Abaloparatide -SC 80 µg 
(Pooled Data#) 
Parameters (Unit)  Statistics  Female  Male  
AUC last (pg*h/mL)  n   64   92 
 Mean (SD)  664.49 (349.232)  670.41 (345.728)  
 Median  618.50  567.53  
 Q1, Q3  469.68, 743.95  390.45, 926.21  
 Min, Max  128.0, 2288.3  156.9, 1832.0  
 MSE  43.654  36.045  
 Gmean 591.28  588.07  
 Ratio of Male/Female (90% CI) [1]  0.9946 (0.8664, 1.1417)  
 Ratio of Male/Female (90% CI) [2]  1.0049 (0.8781, 1.1501)  
AUC 0–∞ (pg*h/mL)  n   61   88 
 Mean (SD)  703.39 (359.555)  724.75 (363.382)  
 Median  644.00  618.39  
 Q1, Q3  505.33, 775.74  428.35, 980.34  
 Min, Max  194.0, 2325.4  176.2, 1923.0  
 MSE  46.036  38.737  
 Gmean 632.53  641.28  
 Ratio of Male/Female (90% CI) [1]  1.0138 (0.8861, 1.1600)  
 Ratio of Male/Female (90% CI) [2]  1.0323 (0.9056, 1.1768)  
Cmax (pg/mL)  n   64   92 
 Mean (SD)  524.69 (168.997)  467.17 (152.786)  
 Median  507.00  455.00  
 Q1, Q3  416.00, 618.00  366.00, 545.00  
 Min, Max  198.0, 1140.0  214.0, 928.0  
 MSE  21.125  15.929  
 Gmean 498.86  443.77  
 Ratio of Male/Female (90% CI) [1]  0.8896 (0.8153, 0.9706)  
 Ratio of Male/Female (90% CI) [2]  0.8943 (0.8195, 0.9758)  
tmax (h) n   64   92 
 Mean (SD)  0.40 (0.191)  0.42 (0.177)  
 Median  0.33 0.33 
 Q1, Q3  0.25, 0.50  0.25, 0.50  
 Min, Max  0.3, 1.1  0.3, 1.1  
 MSE  0.024  0.018  
 Gmean 0.36 0.39 
 P-value [3]  0.4177  
t½ (h) n   62   89 
 Mean (SD)  1.26 (2.270)  1.07 (0.565)  
 Median  0.96 0.95 
 Q1, Q3  0.77, 1.11  0.67, 1.30  
 Min, Max  0.5, 18.7  0.4, 3.2  
 MSE  0.288  0.060  
 Gmean 0.97 0.96 
# The data include  studies  BA058 -05-010, BA058 -05-011, BA058 -05-012, and BA058 -05-014. Ten female subjects 
and 17 male subjects in Study  BA058 -05-014 received 2 doses of abaloparatide -SC; both PK profiles are included in 
the summary table.  
[1] Ratio  is based  on ANOVA  model  with sex as fixed  effect.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 27 of 81 [2] Ratio  is based  on ANOVA  model  with sex and study  as fixed  effects.  
[3] P-value  is based  on T-test 
AUC 0–∞ = area under the plasma concentration -time curve from time zero to infinity; AUC last = area under the plasma 
concentration -time curve from  time zero to the time of the last quantifiable concentration; C max = maximum plasma 
concentration; G mean = geometric  mean; MSE =  standard  error  of the mean;.Q1, Q3 = interquartile range; SD = 
standard deviation; t 1/2 = apparent terminal phase half -life; t max = time to reach maximum plasma concentration 
following drug administration.  
Postdose  BQL  values  were  set to half the LLOQ  for computation  of mean  postdose  concentration  values.  
 
There were also no apparent differences in abaloparatide clearance ( Figure  2). 
 
Figure  2: PK Concentration over Time in Subjects Treated with Abaloparatide -SC 
80 µg (Pooled Data#) 
 
# The data include  studies  BA058 -05-010, BA058 -05-011, BA058 -05-012, and BA058 -05-014. 
Abaloparatide Concentration Mean (+/- SE) (pg/mL)
050100150200250300350400450500550
Time Point (Hour)0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24Female
Male
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 28 of 81 Figure  3: Study BA058 -05-012 – Mean (95% CI) Change from Baseline in Serum 
Calcium over Time by [CONTACT_757988] 80 µg Treatment (Safety 
Population)  
 
In the clinical trial of women with postmenopausal osteoporosis (BA058 -05-003), 
abaloparatide -SC caused increases in serum calcium concentrations, evident at [ADDRESS_1037532] 
administration. Serum calcium concentrations were assessed in b oth male and female subjects in 
Study BA058 -05-012. In this study, male and female subjects were dosed with a single injection 
of 80 µg of abaloparatide -SC. Serum calcium levels were measured at baseline, and at 2, 4, and 
8 hours postdose. Although the lev els across time were slightly higher in males than in females 
(Figure  3), the temporal pattern of change in serum calcium concentration was similar, with the 
maximal concentrations observed approximately 4 hours after dosing.  

Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 29 of 81 Table  2: Pooled Treatment -Emergent Adverse Events – Differences Between Male 
and Female Subjects in Phase 1 Studies (BA05805 -010, BA05805 -010, 
BA05 805-011, BA05805 -012, and BA05805 -014) *  
System Organ Class  
  Preferred Term  Female  
(N = 54)  
n (%)  Male  
(N = 77)  
n (%)  
At Least one TEAE  25 (46.3)  16 (20.8)  
 
Cardiac disorders  2 (3.7)  1 (1.3)  
  Bundle branch block left  1 (1.9)  0 
  Palpi[INVESTIGATOR_814]  1 (1.9)  0 
  Postural orthostatic tachycardia syndrome  0 1 (1.3)  
 
Gastrointestinal disorders  4 (7.4)  4 (5.2)  
  Nausea  3 (5.6)  4 (5.2)  
  Abdominal distension  1 (1.9)  0 
  Abdominal pain  1 (1.9)  0 
  Diarrhoea  1 (1.9)  0 
  Vomiting  0 1 (1.3)  
 
General disorders and administration site conditions  9 (16.7)  4 (5.2)  
  Injection site erythema  8 (14.8)  3 (3.9)  
  Injection site pruritus  5 (9.3)  0 
  Application site erythema  1 (1.9)  0 
  Chills  0 1 (1.3)  
  Injection site haemorrhage  0 1 (1.3)  
 
Infections and infestations  1 (1.9)  [ADDRESS_1037533] infection  1 (1.9)  0 
 
Investigations  1 (1.9)  0 
  Blood pressure increased  1 (1.9)  0 
 
Metabolism and nutrition disorders  1 (1.9)  1 (1.3)  
  Decreased appetite  1 (1.9)  1 (1.3)  
 
Musculoskeletal  and connective tissue disorders  1 (1.9)  1 (1.3)  
  Musculoskeletal pain  1 (1.9)  0 
  Myalgia  0 1 (1.3)  
   
Nervous system disorders  13 (24.1)  10 (13.0)  
  Headache  11 (20.4)  7 (9.1)  
  Dizziness postural  2 (3.7)  2 (2.6)  
  Dizziness  1 (1.9)  2 (2.6)  
  Paraesthesia  0 1 (1.3)  
  Somnolence  0 1 (1.3)  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 30 of 81 System Organ Class  
  Preferred Term  Female  
(N = 54)  
n (%)  Male  
(N = 77)  
n (%)  
Respi[INVESTIGATOR_696], thoracic and mediastinal disorders  2 (3.7)  1 (1.3)  
  Dyspnoea  1 (1.9)  0 
  Oropharyngeal pain  1 (1.9)  0 
  Nasal congestion  0 1 (1.3)  
  Productive cough  0 1 (1.3)  
   
Skin and subcutaneous tissue disorders  1 (1.9)  0 
  Erythema  1 (1.9)  0 
   
Vascular disorders  1 (1.9)  0 
  Orthostatic hypotension  1 (1.9)  [ADDRESS_1037534]  was counted  once  for the same  system  organ  class  and the same  preferred  term. 
Preferred  terms  were  sorted  by [CONTACT_757989].  
TEAE = treatment -emergent adverse event  
 
Abaloparatide has been studied in the male population, and differences in treatment -emergent 
adverse events (TEAEs) were observed between  males and females ( Table  2). In pooled data 
across 4 Phase 1 studies (BA05805 - 010, BA05805 -011, BA05805 -012, and BA05805 -014), 25 
of 54  females (46.3%) and 16 of 77 males (20.8%) experienced at least one TEAE.  
Based on these results, which demonstrated no apparent difference in the systemic exposure of 
abaloparatide -SC between males and females across 4 different Phase 1 clinical trials, together 
with Phase 3 safety and efficacy data showing significant increases in BMD in osteoporotic 
women following 6, 12, and 18 months of treatment with abaloparatide -SC, the 80 -µg dose is 
therefore an appropriate dose for the treatment of men with osteoporosis.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 31 of 81 2. STUDY  OBJECTIVES AND ENDP OINTS  
2.1. Primary Objective and Endpoint  
The primary objective of this prospective controlled study is to evaluate the efficacy and the 
safety of abaloparatide -SC 80 µg per day compared to placebo in men with osteoporosis. The 
primary efficacy endpoint is the percent change from baseline in lumbar spi[INVESTIGATOR_531859] 
12 months.  
2.2. Secondary Endpoints  
The key secondary efficacy endpoints are:  
• Percent change from baseline in total hip BMD at 12 months  
• Percent change from baseline in femoral neck BM D at 12 months  
Additional secondary efficacy endpoints are:  
• Percent change in baseline in:  
− Lumbar spi[INVESTIGATOR_531859] 3 and 6 months  
− Total hip BMD at 3 and 6 months  
− Femoral neck BMD at 3 and 6 months  
− Ultra -distal radius BMD at 3, 6, and 12 months  
− Distal one -third radius BMD at 3, 6, and 12 months  
• Log ratio of post -baseline over baseline in:  
− Serum procollagen type I N -terminal propeptide (s -PI[INVESTIGATOR_680]) at 1, 3, 6, and 
12 months  
− Serum carboxy -terminal cross -linking telopeptide of type I collagen (s -CTX) at 1, 
3, 6, and 1 2 months  
• Proportion of subjects experiencing BMD gains from baseline of >  0%, >  3%, and 
> 6% at the lumbar spi[INVESTIGATOR_050], femoral neck, and total hip at 3, 6, and 12  months  
• Incidence of new clinical fractures at 12 months  
• Proportion of subjects converting from the  categories of osteoporosis to osteopenia or 
to normal at 12  months, where:  
− Osteoporosis is defined as lumbar spi[INVESTIGATOR_757952] T -score ≤ -2.5.  
− Osteopenia is defined as as one of the following:  
o Lumbar spi[INVESTIGATOR_050] > -2.5 and total hip BMD T -score > -2.5 and  < -1.0  
o Lumbar spi[INVESTIGATOR_050] > -2.5 and < -1.0 and total hip BMD T -score > -2.5  
− Normal is defined as lumbar spi[INVESTIGATOR_757953] T -score ≥ -1.0.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 32 of 81 • The percent change in total hip and femoral neck volumetric BMD as measured by 
[CONTACT_621948] (QCT) from baselin e to [ADDRESS_1037535] will be performed in a subset 
of subjects in a selected number of study sites . 
For those subjects who consent to PK sample collection, the PK endpoints are:  
• The plasma concentration of abaloparatide based on sparse PK sampling at the 
following visits:  
− Month 6: postdose PK samples collected 45 minutes ( ±15 minutes) and 2.5  hours 
(±0.5 hour) after abaloparatide -SC injection  
− Month 9: postdose PK samples collected 20 minutes ( ±10 minutes) and 4  hours 
(±0.5 hour) after abaloparatide -SC injection  
− Month 12: a predose sample and a postdose sample collected 1.5  hours 
(±0.5 hour) after abaloparatide -SC injection  
The safety endpoints are:  
• Overall safety and tolerability of abaloparatide -SC in men with osteoporosis as 
assessed by [CONTACT_2695], vital sig ns, electrocardiograms (ECGs), laboratory tests of 
chemistry and hematology, urinalysis, local tolerance, and presence of antibodies  
Subgroup analysis (e.g., age, geography, FRAX (if applicable), prior fracture, and baseline 
BMD, s -PI[INVESTIGATOR_680], testosterone and e stradiol levels) may be performed and will be described in the 
Statistical Analysis Plan (SAP).  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-[ADDRESS_1037536] of a Screening Period (up to 2 months), a Pretreatment Period (1 week), and  a Treatment 
Period (12 months) with a Follow -up Visit [ADDRESS_1037537] 
additional baseline assessments.  
Subjects who remain eligible for study participation will be randomly allocated, using a 
2:[ADDRESS_1037538] ( Section  5.7). The Sponsor 
pharmacovigilance/regulatory personnel m ay also be unblinded for suspected unexpected serious 
adverse reaction (S[LOCATION_003]R) reporting purposes.  
All subjects will receive calcium 500 –1000 mg/day and vitamin D 400 –800 IU/day, or a dose 
determined by [CONTACT_757990] M onitor, according to the 
subject’s need.  
The study  design is presented in Figure 4, below. All subjects will undergo safety, BMD, bone 
marker, and fracture assessments at regular intervals, according to the Schedule of Assessments 
and Procedures ( Table  3). Subjects will be asked if they are willing t o provide PK samples to 
evaluate the amount of abaloparatide in the plasma at various timepoints. Those subjects who 
consent to this sparse PK sampling will have samples collected at Months 6, 9, and 12 as shown 
in Table  4. 
Figure 4: Study BA058 -05-[ADDRESS_1037539] ion 4.1 
and none of the exclusion criteria listed in Section 4.2. Subjects who were screened and excluded 
from this study will be recorded in the electronic case report form (eCRF), as well as the reason 
why they were screen failures . 
4.1. Inclusion Criteria  
1. The subject is a healthy ambulatory male from 40 to 85 years of age (inclusive) with 
primary osteoporosis or o steoporosis associated with hypogonadism.  
2. The subject has a BMD T -score (based on the male reference range as assessed by [CONTACT_54644]) of:  
a. ≤ -2.5 at the lumbar spi[INVESTIGATOR_050] (L1 –L4) or hip (femoral neck or total hip) by [CONTACT_11323] 
X-ray absorptiome try (DXA); or 
b. ≤ -1.[ADDRESS_1037540] a BMD T -score ≤ -2.[ADDRESS_1037541] is in good general health as determined by [CONTACT_723] (including vital signs) and is without evidence of a clinically significant 
abnormality in the opi[INVESTIGATOR_689], or n one for which there is a reasonable 
chance of interfering with the subject’s health and/or medical treatment during the study. 
The subject has a body mass index (BMI) of 18.[ADDRESS_1037542]’s height and weight. In the  case where a subject’s height cannot be 
adequately assessed (e.g., due to vertebral compression fractures or scoliosis), the subject’s 
historical height (as documented in the subject’s medical record) will be used to derive the 
BMI.  
4. Hypogonadal subjects w hose doses of androgens have been stable for at least [ADDRESS_1037543] has serum calcium (albumin -corrected), PTH, serum phosphorus and alkaline 
phosphatase, and thyroid stim ulating hormone (TSH) values all within the normal range 
during the Screening Period. Any subject with an elevated alkaline phosphatase value and 
who meets all other entry criteria must have a normal bone -specific alkaline phosphatase 
to be enrolled. Any s ubject with a TSH value outside of the normal range must have 
central laboratory reported T3 and free T4 values within the normal ranges to be enrolled.  
6. The subject has serum 25 -hydroxyvitamin D values ≥ 20 ng/mL and within normal range. 
Subjects with seru m 25 -hydroxyvitamin D levels <  20 ng/ml may be treated with vitamin 
D and retested once during the Screening Period.  
7. The subject’s systolic blood pressure is ≥ 100 and ≤ 155 mmHg, diastolic blood pressure 
is ≥ 40 and ≤ 95 mmHg, and heart rate is ≥ 45 and ≤  100 bpm (taken sitting or supi[INVESTIGATOR_050]). 
Any recorded values outside of these ranges and assessed by [CONTACT_757991], Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-[ADDRESS_1037544] has no clinica lly significant abnormality of serum hemoglobin, hematocrit, 
white blood cells, and platelets, or usual serum biochemistry: electrolytes, renal function, 
liver function and serum proteins that might be expected to interfere with the subject’s 
health and/or  medical treatment during the study.  
9. In subjects who have partners of childbearing potential, the subject and his partner should 
abstain from sexual intercourse, or use highly effective contraceptive measures (e.g., oral 
contraceptive and condom, intrauter ine device [IUD] and condom, or diaphragm with 
spermicide and condoms; other forms of contraception must be approved by [CONTACT_22955]) when engaging in sexual intercourse throughout the study, and for at least [ADDRESS_1037545] has read, understood, and signed the written informed consent form (ICF).  
4.2. Exclusion Criteria  
General exclusion criteria:  
1. Presence of abnormalities of the lumbar spi[INVESTIGATOR_757954], defined as having at least 2 radiologically evaluable vertebrae within L1 –L4 as 
assessed by [CONTACT_11343].  
Anatomically abnormal vertebrae are excluded if:  
• They are clearly abnormal and non -assessable within the resolution of the system; or  
• There is a more than 1. 0 T-score difference between the vertebra in question and 
adjacent vertebrae.  
2. A BMD T -score of ≤ -3.[ADDRESS_1037546] acement 
(unilateral hip replacement is acceptable).  
4. Fragility fracture within the prior 12 months.  
5. History of severe vertebral fracture or > 2 moderate vertebral fractures.  
6. History of bone disorders (e.g., Paget’s disease) other than osteoporosis.  
7. Subjects  with clinical signs of hypogonadism present at screening who plan to initiate 
testosterone replacement.  
8. History of prior external beam or implant radiation therapy involving the skeleton, other 
than radioiodine.  
9. History of chronic or recurrent renal, hepa tic, pulmonary, allergic, cardiovascular, 
gastrointestinal, endocrine, central nervous system, hematologic or metabolic diseases, or 
immunologic, emotional and/or psychiatric disturbances to a degree that would interfere 
with the interpretation of study da ta or compromise the safety of the subject.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 36 of 81 10. History of Cushing’s disease, growth hormone deficiency or excess, hyperthyroidism, 
hypo - or hyperparathyroidism or malabsorptive syndromes within the past year.  
11. History of significantly impaired renal function ( serum creatinine >  177 μmol/L or 
> 2.0 mg/dL). If the serum creatinine is > 1.5 and ≤ 2.0 mg/dL, the calculated creatinine 
clearance (Cockcroft -Gault) must be ≥ 37 mL/min.  
12. History of any cancer within the past 5 years (other than basal cell or squamous cancer of 
the skin).  
13. History of osteosarcoma at any time.  
14. Subjects with hereditary disorders predisposing them to osteosarcoma.  
15. History of nephrolithiasis or urolithiasis within the past 5 years.  
16. Subjects known to be positive for Hepatitis B, Hepatitis C, human immunodeficiency 
virus (HIV) -1 or HIV -2. Testing is not required in the absence of clinical signs and 
symptoms suggestive of HIV infection or acute or chronic hepatitis.  
Medication -related exclusion criteria:  
17. Known history of hypersensitivity to any of the test materials or related compounds.  
18. Prior treatment with PTH - or PTHrP -derived drugs, or bone anabolic drugs including 
abaloparatide or teriparatide, or PTH(1 -84). 
19. Prior treatment with intravenous (IV) bisphosphonates at any time or oral 
bisphospho nates within the past 3 years. Subjects who had received a short course of oral 
bisphosphonate therapy (3 months or less) may be enrolled as long as the treatment 
occurred [ADDRESS_1037547] 5 years or prior treatment with gallium 
nitrate or other bone -acting investigational agents at any time. Limited use of gallium 
citrate/nitrate for diagnostic purposes (i.e., a gallium scan) is not exclusionary.  
21. Prior treatment with calcitonin or tibol one in the past [ADDRESS_1037548] vitamin D metabolism (phenobarbital, 
phenytoin, carbamazepi[INVESTIGATOR_050], or primidone) or with chronic heparin within the 6 months 
prior to the  Screening Period.  
24. Treatment with anabolic steroids or calcineurin inhibitors (cyclosporin, tacrolimus) 
within the past 90 days  
25. Daily treatment with oral, intranasal, or inhaled corticosteroids within the 12  months 
prior to the Screening Period. Occasional  use of all corticosteroids (for seasonal allergies 
or asthma) is not exclusionary.  
26. Exposure to an investigational drug within the 12 months prior to the Screening Period.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 37 of 81 Lifestyle -related exclusion criteria:  
27. Abnormal nutritional status (as assessed by [CONTACT_3433] e Investigator), vitamin D intake of 
≥ 4,000  IU/day or vitamin A intake of ≥ 10,000 IU/day. Short term use of high doses of 
vitamin D to increase endogenous vitamin D levels for study entry is not exclusionary.  
28. Subject is known to consume > 2 alcoholic dri nks per day, to use illegal drugs, or to 
abuse tobacco or marijuana (medicinally or recreationally where legal) within [ADDRESS_1037549] withdraw subjects from the stu dy for the following reasons:  
• Continuing significant deterioration from baseline (≥  7%) of BMD at spi[INVESTIGATOR_69648] 
(after confirmation of the finding)  
• Hypercalcemia as described in Section  4.7.1  
• Severe hypersensitivity to abaloparatide  
• Refusal of treatment  
• Inability to complete study procedures  
• Lost to follow -up 
The Investigator also has the right to withdraw subjects from the study for any of the following 
reasons:  
• Serious AEs (as described in Section  7.1.3 ) 
• A complex of AEs which, in the judgment of the Investigator justifies tre atment 
cessation  
• Serious intercurrent illness  
• Noncompliance  
• Protocol deviations  
• Administrative reasons  
Subjects will be offered the opportunity to discontinue from the study for the following reasons 
after site consultation with the Study Medical Monitor:  
• Incident vertebral or nonvertebral fragility fracture  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-[ADDRESS_1037550] withdraws from the study due to the ongoing coronavirus disease 2019 (COVID -19) 
global pandemic, this information will be captured in the eCRF so that it can be described in the 
clinical study report a t the end of the study, in line with the Food and Drug Administration 
(FDA) Guidance on Conduct of Clinical Trials of Medical Products during COVID -19 Public 
Health Emergency ( FDA 2021 ).  
The reason for the withdrawal should be recorded in the eCRF as COVID -19, if applicable, and 
include as many details as possible (e.g., the subject had a positive test result or decided to 
withdraw from the study due to personal choice related to COVID -19 concerns).  
4.3.2.  Handling of Participant Wi thdrawals or Terminations  
If a subject is withdrawn or discontinued from the study, the reason for withdrawal from the 
study is to be recorded in the source documents and on the CRF. All subjects withdrawn prior to 
completing the study should be encouraged  to complete study procedures scheduled for the 
Month  12/Early Termination visit as soon as possible, and to return in 1 month for a Follow -up 
Visit. All AEs should be followed as described in Section  7. Subjects who discontinue or are 
withdrawn from the study will not be replaced.  
4.4. Concomitant Medications  
Calcium (500 –1000 mg/day) and vitamin D (400 –800 IU/day) supplements, or a dose 
determi ned by [CONTACT_757992],  according to the 
subject’s need, are required to be administered daily from the Pretreatment Period until the end 
of the Treatment Period. The doses and schedule of calcium and vitamin D supplements, which 
are part of the study medication protocol, should be adhered to and not be changed other than for 
medical necessity. The supplements should be taken in the evening with or without food or as 
otherwise instructed by [CONTACT_737].  
For any required concomitant chronic medication, such as statins or antihypertensives, the 
subject must be on a stable dose for [ADDRESS_1037551] be well -controlled.  
The occasional use of over -the-counter medications at labeled doses (e.g., ibuprofen or 
acetaminophen) for headache or minor discomfort is allowed. These are to be recorded in the 
source records and entered in the appropriate CRF. S ubjects should not take any other 
medications, including over -the-counter medications, herbal medications, or mega -doses of 
vitamins during the study without prior approval of the Investigator.  
If it becomes necessary for a subject to take any other medica tion during the study, the specific 
medication(s) and indication(s) must be discussed with the Investigator. All concomitant 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-[ADDRESS_1037552]’s medical 
record or source document and transcribe d into the eCRF.  
4.5. Prohibited Medications  
Please refer to Section  4.[ADDRESS_1037553] an abnormal nutritional status 
(abnormal diets, excessive or unusual vitamin or herbal intakes, malabsorption).  
Occasional short term (≤  3 months) use of corticosteroids for seasonal allergies or  asthma is not 
prohibited. Subjects who require chronic treatment with either an anticonvulsant (phenobarbital, 
phenytoin, carbamazepi[INVESTIGATOR_050], or primidone), or with heparin will be discontinued.  
4.6. Premature Termination or Suspension of Study  
This study may be temporarily suspended or prematurely terminated if there is sufficient 
reasonable cause. Written notification documenting the reason for study suspension or 
termination will be provided by [CONTACT_261683] 
(PI), and regulatory authorities. If the study is prematurely terminated or suspended, the PI [INVESTIGATOR_757959] (IRB) / Independent Ethics Committee (IEC) 
and will provide the reason(s) for the termination or suspension.  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants.  
• Insufficient compliance with protocol requirements.  
• Data that are not sufficiently compl ete and/or evaluable.  
• Decision of Sponsor.  
Study may resume once concerns about safety, protocol compliance, or data quality are 
addressed and satisfy the Sponsor, IRB/IEC, and/or regulatory agencies, if applicable.  
4.7. Temporary Suspension of Treatment  
The Investigator has the right to suspend treatment with study medication for up to 
[ADDRESS_1037554] from the study. 
Reasons for temporary suspension of treatment may include a medical reason unrelated  to an 
adverse event (e.g., a planned procedure), or important social or administrative events. The 
reason for the suspension of treatment is to be documented in the CRF and in source documents. 
Such subjects should not be unblinded as to study medication.  
When treatment is restarted, the subject should resume treatment with the next scheduled dose 
and continue until the scheduled End -of-Treatment. If the treatment suspension is due to a 
medical emergency and study medication needs to be unblinded, please r efer to Section  5.[ADDRESS_1037555] treatment 
with calcium and vitamin D temporarily suspended as described below.  
4.7.1.  Treatment Algorithm in Subjects Who Develop Hypercalcemia  
Hypercalcemia is defined as any serum calcium (albumin -corrected) that is ≥ 0.3 mg/dL 
(equivalent to >  0.08 mmol/L) above the upper  limit of normal (ULN). For this study, the normal 
range, ULN and lower limit of normal (LLN) for serum calcium (albumin -corrected) are 
determined by [CONTACT_2237].  
For any predose serum calcium (albumin -corrected) value which is ≥ 0.3 to 1.0 mg/d L, 
corresponding to ≥ 0.08 to 0.25 mmol/L, above the ULN (inclusive), confirm hypercalcemia by 
[CONTACT_740] a new serum sample as soon as possible after the result is received ( Figure  5). 
• If the repeat serum calcium (albumin -corrected) is above the LLN up to <  0.3 mg/dL 
(equivalent to <  0.08 mmol/L) above the ULN, the subject should continue study drug 
administration together with Calcium and vitamin D suppleme ntation.  
• If a subject’s predose serum calcium is elevated on repeat testing, calcium and 
vitamin  D supplementation should be withheld. The subject is to continue study drug 
administration during this interval.  
• If the subject’s predose serum calcium remains  elevated [ADDRESS_1037556] continues in the study (with calcium and vitamin D supplements) and had an 
epi[INVESTIGATOR_44715] a predose serum calcium (albumin -corrected) value of ≥ 0.3 to 1.0 m g/dL 
(correspondi ng to ≥ 0.08 to 0.25 mm ol/L) above  the ULN, repeat testing  of the  predose serum 
calcium ( albumin -corrected). 
• If the subject’s serum calcium (albumin -corrected) value again returns to normal 
when not taking calcium and vitamin D supplements, the subject may continue in the 
study without calcium and vitamin D supplements.  
• If the retest is still elevated, contact [CONTACT_757993].  
For any serum c alcium (albumin -corrected) value >  1.0 mg/dL above the ULN: 
• Discontinue calcium and vitamin D supplements and discontinue the study drug as 
soon as the result is received. Confirm hypercalcemia by [CONTACT_740] a new serum 
sample as soon as possible.  
• If the result of the retest remains >  1.0 mg/dL above the ULN, perform a  second retest 
after 3 days without calcium and vitamin D supplements and study drug.  
− If the second retest is normal, the subject may continue in the study and resume 
study drug including the calcium and vitamin D supplements.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 41 of 81 − If the second retest is still  elevated, contact [CONTACT_757994].  
• If the subject continues in the study and has a repeat epi[INVESTIGATOR_757960] 
> 1.0 mg/dL above the ULN, contact [CONTACT_757993].  
4.7.2.  Treatment Algorithm in Subjects Who Develop Hypercalciuria  
For a urine calcium:creatinine ratio > 0.4 mg/mg, corresponding to > 1.131 mmol/mmol, check 
the subject’s predose serum c alcium and apply the algorithm outlined in Section  4.7.1  if calcium 
is elevated.  
If the calcium:creatinine ratio is > 0.4 mg/mg and the serum calcium i s normal:  
• Discontinue calcium and vitamin D supplements and recheck urine calcium:creatinine 
values after 7 days.  
− If the urine calcium:creatinine ratio continues to be > 0.4 mg/mg in the presence 
of normal serum calcium, the subject may continue in the stu dy under medical 
supervision (and without receiving additional calcium and vitamin D 
supplements).  
− If the urine calcium:creatinine ratio returns to normal, the subject may restart 
calcium and vitamin D supplements and continue in the study.  
• If the subject restarts the serum calcium and vitamin D supplements and 
hypercalciuria returns, calcium and vitamin D supplementation should be terminated. 
The subject may continue in the study under medical supervision.  
Therefore, subjects with hypercalciuria will not b e discontinued from the study in the absence of 
hypercalcemia except at the discretion of the Investigator.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
 
Study BA058 -05-019 Amendment 6       Page 42 of 81  
Figure  5: Treatment Algorithm in Subjects Who Develop Hypercalcemia  
 
*For  any predose serum calcium (albumin-correcte d) > 1.0 mg/dL (> 0.25 mmol/L) above the upper limit of normal (ULN), immediately discontinue calcium, vitamin D, 
and study drug 
**ULN, lower limit of normal, and normal ranges are determined per the central laboratory 
*** If applicable, also consider restartin g/continuing vitamin D and calci um supplementation after consultation with the Sponsor 

Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
 
Study BA058 -05-[ADDRESS_1037557] -use pen. The pen is 
intended to deliver 30  once daily abaloparatide doses of 80  µg in 40  µL of solution. Each pen 
contains 3120  μg/1.[ADDRESS_1037558] -use pen. The pen is intended to deliver 30  once daily placebo 
doses of 80  µg in 40  µL of fluid when inserted into the Pen Injector device.  
Additional information will be provided to clinical sites in a separate Pharmacy Manual 
including instructions on how to use the injection pen.  
5.1.2.  Calcium and Vitamin D Supplements  
Calcium (500 –1000 mg) and vitamin D (400 –800 IU) supplements will be sourced locally by 
[CONTACT_757995].  
5.2. Packaging, Labeling and Storage  
5.2.1.  Packaging and Labeling  
Abaloparatide -SC and placebo will be supplied and packaged a s identical injection pens. All 
packaging operations will be performed in accordance with Good Manufacturing Practices 
(GMP).  
Study medication will be provided and replaced via the interactive response technology (IRT) 
on clinic visit days. If clinic visit s are not possible, study medication may also be delivered to 
the subject’s home. Labeling will include a caution statement and other information required 
by [CONTACT_31665]. A detailed study drug dispensation plan will be provided in 
the Phar macy Manual.  
Calcium and vitamin D supplements will be provided as packaged by [CONTACT_757996].  
5.2.2.  Storage  
While at the clinical site, abaloparatide and placebo injection pens must be stored in a secure, 
limited access , temperature monitored refrigerator at 2° to 8°C (36° to 46°F) until dispensed 
for use to a study subject or until returned to the Sponsor.  
After the abaloparatide -SC or placebo injection pen is used for the first time, the pen may be 
stored for 30 days a t room temperature, 68°F to 77°F (20°C to 25°C). Unused pens should be 
refrigerated until initial use. Instructions regarding the storage and handling of the study drug 
after dispensation to subjects will be provided to sites in the Pharmacy Manual.  
Calciu m and vitamin D supplements should be stored according to the manufacturer 
recommendations on the bottle.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-[ADDRESS_1037559]’s treatment. 
Information regarding treat ment assignment will reside solely within the IRT, as part of the 
study blinding. Once a kit number has been assigned, it may not be reused. Refer to the IRT 
manual for additional details on IRT instructions.  
Prior to study start, the Sponsor statistician will be responsible for overseeing the preparation 
of the master randomization scheme that will be used to package study medication into kits 
and for the IRT.  
5.4. Dosing and Administration  
Subjects will self -administer a single daily dose of [ADDRESS_1037560] -injection procedures ; study personnel may administer the study 
medication. For the Month [ADDRESS_1037561] 
study medication with the abaloparatide -SC/Placebo injection pen. If a subject requires 
assistance with study medication administration, an individual (e.g., a family member) who 
has been trained by [CONTACT_757997].  
Subjects will also be provided written instructions on how to use the abaloparatide -
SC/Placebo injection pen. Subjects will be instructed by [CONTACT_757998]. I f the cartridge contents are not clear and 
colorless, or if the contents contain particles, the subjects will be instructed not to use the pen 
and to contact [CONTACT_744]. Injections should be administered in the 
morning and preferab ly at the same time each day. If a dose is missed, the dose should be 
administered as soon as possible up to [ADDRESS_1037562] in the diary beginning on Day 2 
and continuing through Day 7 in Month 1 (Visit 4) and beginning on Day [ADDRESS_1037563] compliance will be ascertained by 2 methods: subject 
diaries and  measuring the residual drug in the cartridge.  
Discrepancies will be discussed with the subjects, documented in the medical charts, and 
recorded in the eCRF as appropriate. If a subject does not take all study medication 
(abaloparatide -SC, placebo, calcium , and vitamin D supplements), the reason for the missed 
dosing is to be recorded by [CONTACT_277037].  
If a subject demonstrates continued noncompliance of study drug dosing despi[INVESTIGATOR_363513], the Investigator should contact [CONTACT_757999].  
5.6. Drug Accountability  
The Investigator or designated site staff will maintain records documenting the dates and 
amounts of the following:  
• Study drug received  
• Study drug dispensed to the subjec ts 
• Study drug returned by [CONTACT_748]  
• Study drug returned to RADIUS/designee or destruction of study drug on site  
Subjects will be instructed to return all used and unused study drug to the site. The study drug 
will be retained at the site until inventori ed by [CONTACT_758000]. The study monitor will verify study drug records and inventory throughout the 
study.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-[ADDRESS_1037564] any such unblinding and notify the Sponsor 
Medical Monitor of the unblinding event. The study monitor will not be apprised of the actual 
treatment assignment. In addition, the Sponsor Medical Monitor has the ability to unblind the 
study medication in a  medical emergency.  
If the Investigator determines that the medical event that resulted in unblinding of the study 
medication is not treatment related (relationship is documented as “none”; see Section  7.1.1  
for definitions of relationship), the subject may continue treatment and participation in the 
study, providing no more than [ADDRESS_1037565] dose of study medication 
(refer t o Section  4.7 for details regarding temporary suspension of treatment). If the subject 
discontinues from further treatment with study medication, they  should undergo the 
Month  12/Early Termination and the Month 13 Follow -up Visit as outlined in Section  6.2.7 , 
and the Schedule of Assessments and Proce dures ( Table  3). 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6   Page 47 of 81 6. STUDY PROCEDURES AND  SCHEDULE  
6.1. Study Procedures  
6.1.1.  Study -Specific Procedures  
The study -specific assessments are detailed in this section and  outlined in Table  3. Any 
results falling outside of the reference ranges may be repeated once time during the Screening 
Period at the discretion of the Investigator.  
6.2. Study Schedule  
This study is comprised of 9 clinic visits. Study assessments are to be performed according to 
the Schedule of Assessments and Procedures ( Table  3). There is a ± [ADDRESS_1037566] of a Screening Period (up to 2 months), a Pretreatment Period 
(1 week), a Treatment Period (12 months), and a Follow -up Visit (1 month). During the 
Treatment Pe riod, subjects will have clinic visits for study -related protocol procedures at 
Day 1, Month  1, Month 3, Month 6, Month [ADDRESS_1037567]’s consent and in compliance with country, state, and local requirements, to have a 
study visit conducted at the subject’s home by [CONTACT_6624]. If this occurs, blood and/or urine 
samples may be collected at the subject’s home and then sent to the central laboratory for 
processing and analysis.  Study drug may also b e delivered to the subject’s home, if needed , to 
enable the subject to continue administering their study drug daily . 
 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-019 Amendment 6       Page 48 of 81 
 Table  3: Schedule of Assessments and Procedures  
 Visit  1 2 3 4 5 
 6 7 8 9 
Procedure  Study Day/Month:  Screening  Pretreatmen
t Day 1  Month 
1 Month 3  Month 
6 Month 9  Month  12/ 
Early 
Termination  Month 13 
Follow -
up 
Visit Window (Days)  N/A1 ± 4 ± 4 ± 4 ± 4 ± 4 ± 4 ± 4 ± 7 
Informed consent  X         
Verification of entry criteria  X X        
Physical examination 2 X         
Review of medical history 3 X         
Symptom -directed physical 
examination   X X X X X X X X 
Vital signs4 X X X X X X X X X 
Weight measurement  X  X X  X  X  
Height measurement5 X X X X X X X X X 
Electrocardiogram6 X  X     X X 
Urinalysis (dipstick)7 X   X  X  X  
Chemistry blood collection  X   X  X  X  
Hematology blood collection  X   X  X  X  
Coagulation (PT and PTT) blood 
collection  X       X  
PTH (1–84) X       X  
25-hydroxyvitamin D level  X       X  
1,25-dihydroxy vitamin D level  X       X  
Total testosterone and SHBG  X       X  
Estradiol  X         
Thyroid stimulating hormone8 X         
PK samples (see Table  4)      X X X  
Study medication assignment via IRT    X       
Injection training for subjects   X        
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
 
Study BA058 -05-019 Amendment 6       Page 49 of 81 Table  3: Schedule of Assessments and Procedures (Continued)  
 Visit  1 2 3 4 5 
 6 7 8 9 
Procedure  Study 
Day/Month:  Screening  Pretreatment  Day 1  Month 
1 Month 3  Month 
6 Month 9  Month  12/ 
Early 
Termination  Month 13 
Follow -up 
Visit Window (Days)  N/A1 ± 4 ± 4 ± 4 ± 4 ± 4 ± 4 ± 4 ± 7 
Calcium and vitamin D supplements   Daily administration   
Study medication administration    Daily administration   
Serum markers of bone metabolism  
(s-PI[INVESTIGATOR_686] s -CTX)    X X X X  X  
Serum calcium and albumin9   X X X X X   
24-hour urine collection (for 
calcium:creatinine and creatinine 
clearance)10   X  X     
Radiologic (lumbar and thoracic 
vertebrae) assessments  X         
Symptom  driven spi[INVESTIGATOR_757961]11  X X X X X X X  
BMD of lumbar spi[INVESTIGATOR_050], total hip , and 
femoral neck by [CONTACT_11324]12 X    X X  X  
BMD of wrist by [CONTACT_11324]13   X  X X  X  
vBMD of hip by [CONTACT_678800]14   X     X  
Sample for immunogenicity testing15   X X X X X X X 
Investigator assessment of local 
tolerance (dermal reactions assessment)    X X X X X   
Subject assessment of local tolerance16   X    X   
Subject diary review17   X X X X X X  
Document AEs and concomitant18 
medications  At any time, question subjects at every visit  
Drug supply/resupply/accountability    X X X X X X  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
 
Study BA058 -05-019 Amendment 6       Page 50 of 81 1. The window for screening activities is 60 days. Due to the ongoing COVID -19 pandemic or other local/widespread emergencies, if there is a delay in the screening process 
that would result in a subject remaining in screening for greater than [ADDRESS_1037568] be reported 
within 30 days prior to randomization.  
2. A complete physical examination includes a review of the following systems: head/neck/thyroid, eyes/ears/nose/throat, resp iratory, cardiovascular, l ymph nodes, abdomen, 
skin, musculoskeletal, and neurological. Breast, anorectal, and genital examinations will be performed when medically indicat ed. After screening, any clinically 
significant abnormal findings in physical examinations should be reported as AEs.  
3. Including alcohol and tobacco use assessment.  
4. Blood pressure, heart rate, body temperature, and respi[INVESTIGATOR_648760]. Only bl ood pressure, heart rate and respi[INVESTIGATOR_757962] -hour post dose at each study visit during the Treatment Period. All blood pressure assessments need to be orthostatic.  
5. Height is to be measured at each visit in the standing position using a medical stadiometer.  
6. ECGs are to be performed predose and one -hour postdose during the Treatment Period.  
7. All routine urinalysis will be performed on a sample freshly voided during the visit and sent to a central lab for microscopy  if test is positive for micro -organisms via 
dipstick.  
8. Reflex testing of T3 and free  T4 will be performed by [CONTACT_758001] -of-range TSH result.  
9. Serum calcium and albumin will be measured predose from the standard chemistry panel on Month [ADDRESS_1037569] entry into the Screening Period (Visit 1) of the study (signed informed consent) 
until [ADDRESS_1037570] be reported to the Sponsor or its desi gnee.  
 
AE = adverse event; BMD = bone mineral density; DXA = dual energy X -ray absorptiometry; IRT = Interactive  response technology; PT = Prothrombin time; PTH = 
Parathyroid hormone; PTT = Partial thromboplastin time; QCT = quantitative CT; s -CTX = serum carboxyl -terminal cross -linking telopeptide of type I collagen; s -PI[INVESTIGATOR_680] = 
serum procollagen type I N -terminal pro peptide; SAE = serious adverse event; SHBG = Sex hormone binding globulin; vBMD = volumetric bone mineral density  
 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
 
Study BA058 -05-019 Amendment 6       Page 51 of 81 Table  4: Schedule for Pharmacokinetic Sample Collections  
Study Visit  Predose  Postdose  
Within 10  min 
before injection  20 min ±  
10 min  45 min ±  
15 min  1.5 hours  
± 0.5 hours  2.5 hours  
± 0.5 hours  4 hours  
± 0.5 hours  
Month 6    
X  X  
Month 9   X   
 X 
Month 12  X   
X   
Note: This schedule only applies to those subjects who consent to have PK samples collected during the study.  
min = minute; PK = pharmacokinetics  
 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
Study BA058 -05-[ADDRESS_1037571] sign and date a study -specific informed consent form (ICF) before any study -
specific procedures can be performed. The consent forms will comply with all applicable 
regulations governing the protection of human subjects. An ICF, approved by [CONTACT_758002]'s IRB/IEC must be used. The Investigator or designee must record the date w hen the ICF 
was signed in the  subject’s source document.  
6.2.3.  Assigning Subject Numbers  
Once a subject has signed an ICF, a subject number will be assigned. The subject will retain this 
number for the entire study.  
6.2.4.  Subject and Disease Characteristics  
Subject and disease characteristics include the following: demographics, medical history, height, 
and weight.  
Medical history will be elicited from each subject during screening. Based on the medical 
history, the subject will be assessed for any disqualifying medi cal conditions as specified in the 
inclusion and exclusion criteria. The medical history shall include a complete review of systems, 
past medical and surgical histories, and any allergies.  
Subjects included into the study based on a history of low -trauma n onvertebral fractures must 
have sufficient source documentation in the form of a medical report or radiographic films as 
evidence of such history.  
6.2.5.  Screening Period (Visit 1)  
Signed informed consent will be obtained and eligibility for study entry assessed . The following 
baseline screening evaluations will be performed:  
• Physical examination  
• Review of medical history, including alcohol, tobacco, and drug use  
• Review of concomitant medications  
• Height  
• Weight  
• ECG  
• Orthostatic blood pressure and vital signs  
• Lumbar  and thoracic spi[INVESTIGATOR_700] (anteroposterior and lateral)  
• BMD assessments of lumbar spi[INVESTIGATOR_050], total hip, and femoral neck by [CONTACT_11324]  
− BMD T scores may be rounded off to the nearest tenth (i.e., rounded off to one 
decimal point) for the purpose of assessing stu dy eligibility per protocol.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 53 of 81 − For screening purposes, DXA scans of the lumbar spi[INVESTIGATOR_050], total hip, and femoral 
neck taken with a study -approved scanner up to [ADDRESS_1037572] eligibility.  
• Laboratory testing of serum chemistry, hematology, coagulation, and urine dipstick  
• PTH, 25 -hydroxyvitamin D, and 1,25-dihydroxy vitamin D level  
• Serum total testosterone and sex hormone binding globulin (SHBG)  
• Estradiol and TSH level  
Subjects who do not meet the 25 -hydroxyvitamin D entry criterion may receive vitamin D 
supplementation and be retested once during the Screening Period. Similarly, subjects with 
minor elevations of PTH may be retested one time after vitamin D supplementati on. Subjects 
whose laboratory tests do not fall within the specified ranges as detailed in the 
inclusion/exclusion criteria may have the samples redrawn and the tests repeated once during the 
Screening Period. If upon retesting, the values fall within the inclusion/exclusion criteria, the 
subject may enter the study. All subjects enrolled following retesting must have safety laboratory 
results reported within 30 days prior to randomization.  
The window for screening activities is 60 days. Due to the ongoing  COVID -19 pandemic or 
other local/widespread emergencies, there may be screening process delays. In the case of 
screening process delays that result in a subject remaining in the Screening Period for greater 
than [ADDRESS_1037573] signs the informed consent.  
6.2.6.  Pretreatment Period (Visit 2)  
Subjects who are eligible for the study on  the basis of screening evaluations will enter the 
Pretreatment Period of the study and will be provided the calcium and vitamin D supplements 
required until the next study visit. All subjects will be required to commence calcium 500 –
1000  mg/day and vitami n D supplements 400 –800 IU/day (or doses determined by [CONTACT_758003], according to the subject’s need). 
Subjects will also undergo training for medication self -administration during this period; AEs 
will be reco rded, and the following procedures will be performed:  
• Symptom -directed physical exam, including assessment for potential vertebral 
fracture  
• Verification of study entry criteria  
• Height  
• Orthostatic blood pressure and vital signs  
• Clinical assessment of new fr actures  
• Instruct subject on procedures and provide with supplies for collecting a 24 -hour 
urine sample (the sample is to be collected on the day prior to Day 1)  
• Injection training for subjects  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 54 of 81 6.2.7.  Treatment Period  
Subjects who remain eligible for study partici pation will be randomly allocated through the IRT, 
using a 2:[ADDRESS_1037574] 
(Section  5.7). The Sponsor pharmacovigilance/regulatory personnel may also be unblinded for 
S[LOCATION_003]R reporting purposes. During the Treatment Period, subjects will self -administer a single 
subcutaneous dose of study medication once a day .  
At each clinic visit during this period, recent health status will be obtained, the diary reviewed, 
AEs collected, and orthostatic blood pressure and vital signs performed. Laboratory assessments 
of chemistry and hematology and urinalyses will be obtained at M onth 1, Month 6, and 
Month  12, and a 24 -hour urine will be collected on the day prior to Visit 1 and on the day prior 
to Visit 5 (Month 3). Clinical assessments for fracture will be performed at each visit. Source 
documentation (imaging report and/or film along with other supporting documentation as 
appropriate) will be collected from each site to confirm fracture.  
Subjects will have BMD assessed by [CONTACT_35682][INVESTIGATOR_050], total hip, and femoral neck at 
screening and Months 3, [ADDRESS_1037575] will be performed in a 
subset of subjects at a selected number of study sites based upon availability. Bone turnover 
marker assessments (s -PI[INVESTIGATOR_680] a nd s-CTX) will be performed on Day 1, and Months 1, 3, 6, and 
12.  
6.2.8.  Visit 3 (Day 1)  
• A [ADDRESS_1037576] void and 
begin a 24 -hour urine collection on the day prior to the clinic visit  
• Symptom driven p hysical exam, including assessment for potential vertebral fracture  
• Collect blood for immunogenicity testing  
• ECGs (predose and one -hour postdose)  
• Orthostatic blood pressure and vital signs  
• Height  
• Weight  
• Serum calcium and albumin (predose and [ADDRESS_1037577] dose)  
• Measurement of volumetric bone density at the hip by [CONTACT_678800]  
• Clinical assessment of new fractures  
• AE and concomitant medication review  
• Wrist DXA  
• Bone turnover markers (s -PI[INVESTIGATOR_686] s -CTX)  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 55 of 81 • Randomization and study medication (abaloparatide -SC or placebo) wil l be assigned 
through the IRT  
• Dispense study medication  
• First dose of study medication will be administered by [CONTACT_758004]  
• Investigator assessment of local tolerance, within 5 minutes and at 1 hour following 
administration  
• Instruct subject on completion of diary, including subject assessment of local 
tolerance, within 5 minutes and at 1 hour following administration, will need to be 
done beginning on Day 2 and continuing through Day 7 of Month 1.  
6.2.9.  Visit 4 (Month 1)  
• Symptom driven physical exam, including assessment for potential vertebral fracture  
• Collect blood for immunogenicity testing  
• Orthostatic blood pressure and vital signs  
• Height  
• Weight  
• Laboratory testing of serum chemistry, hematology, and urine dipstick  
• Serum calcium and albumin (predose  and [ADDRESS_1037578] dose)  
• Dispense study medication  
• Self-administration of study medication when directed by [CONTACT_758005]  
• Clinical assessment of new fractures  
• AE and concomitant medication review  
• Bone turnover markers (s -PI[INVESTIGATOR_686] s -CTX)  
• Investigator assessment of local tolerance, within 5 minutes and at 1 hour following 
administration  
• Review subject diary  
• Provide subject with supplies for collecting a 24 -hour urine sample (the sample is to 
be collected on the day prior to the Month 3 visit).  
6.2.10.  Visit 5 (Month 3)  
• A [ADDRESS_1037579] void and 
begin a 24 -hour urine collection on the day prior to the clinic visit  
• Symptom -directed physical examination, including assessment f or potential vertebral 
fracture  
• Collect blood for immunogenicity testing  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 56 of 81 • Orthostatic blood pressure and vital signs  
• Height  
• BMD assessments of lumbar spi[INVESTIGATOR_050], total hip, femoral neck, and wrist by [CONTACT_11324]  
• Bone turnover markers (s -PI[INVESTIGATOR_686] s -CTX)  
• Dispense study me dication  
• Self-administration of study medication when directed by [CONTACT_758005]  
• Serum calcium and albumin (predose and [ADDRESS_1037580] dose)  
• Clinical assessment of new fractures  
• AE and concomitant medication review  
• Investigator assessment of local tolerance, within 5 minutes and at 1 hour following 
administration  
• Review subject diary  
6.2.11.  Visit 6 (Month 6)  
• Symptom -directed physical examination, including assessment for potential vertebral 
fracture  
• Collect blood for immunogenicity testing  
• Height  
• Weight  
• Orthostatic blood pressure and vital signs  
• Dispense study medication  
• Self-administration of study medication when directed by [CONTACT_758005]  
• Only for subjects who consent to provide PK  samples: Collect PK samples at 45 
minutes (±15 minutes) and 2.5 hours (±0.5 hour) after injection  
• Laboratory testing of serum chemistry, hematology, and urine dipstick  
• Serum calcium and albumin (predose [from chemistry panel] and [ADDRESS_1037581] dose)  
• BMD as sessments of lumbar spi[INVESTIGATOR_050], total hip, femoral neck, and wrist by [CONTACT_11324]  
• Bone turnover markers (s -PI[INVESTIGATOR_686] s -CTX)  
• Clinical assessment of new fractures  
• AE and concomitant medication review  
• Investigator assessment of local tolerance, within 5 minutes and at 1 ho ur following 
administration  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 57 of 81 • Review subject diary  
6.2.12.  Visit 7 (Month 9)  
• Symptom -directed physical examination, including assessment for potential vertebral 
fracture  
• Collect blood for immunogenicity testing  
• Orthostatic blood pressure and vital signs  
• Height  
• Dispense study medication  
• Self-administration of study medication when directed by [CONTACT_758005]  
• Only for subjects who consent to provide PK samples: Collect PK samples at 20 
minutes (±10 minutes) and 4 hours (±0.5 hour)  after injection  
• Serum calcium and albumin (predose and 4 hours postdose)  
• Clinical assessment of new fractures  
• AE and concomitant medication review  
• Investigator assessment of local tolerance, within [ADDRESS_1037582] assessment 
of local tolerance, within 5 minutes and at 1 hour following administration, beginning 
on Day 2, and continuing through Day 7 in Month 9  
• Review subject diary  
6.2.13.  Visit 8 (Month 12)/Early Termination  Visit  
• Symptom -directed physical examination, including assessment for potential vertebral 
fracture  
• Collect blood for immunogenicity testing  
• ECG  
• Weight  
• Height  
• Orthostatic blood pressure and vital signs  
• Only for subjects who consent to provide PK samples an d attend the Month 12 visit: 
Collect a predose sample within 10  minutes before injection  
• Self-administration of study medication when directed by [CONTACT_758006] 7 (Note: Applicable only  to 
subjects completing a Month 12 visit)  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 58 of 81 • Only for subjects who consent to provide PK samples and attend the Month 12 visit: 
Collect a postdose sample at 1.5  hours (±0.5 hour) after injection  
• PTH, 25 -hydroxyvitamin D, and 1,25-dihydroxy vitamin D level  
• Laboratory testing of serum biochemistry, hematology, coagulation and urine dipstick  
• BMD assessments of lumbar spi[INVESTIGATOR_050], total hip, femoral neck, and wrist by [CONTACT_11324]  
• Measurement of volumetric bone density at the hip by [CONTACT_678800]  
• Bone turnover markers (s -PI[INVESTIGATOR_686] s -CTX ) 
• Serum total testosterone and SHBG  
• Clinical assessment of new fractures  
• AE and concomitant medication review  
• Review subject diary  
6.2.14.  Visit 9/Safety Follow -up 
• Symptom -directed physical examination, including assessment for potential vertebral 
fracture  
• Collect  blood for immunogenicity testing  
• Record vital signs  
• Height  
• ECG  
• All AEs, including SAEs, will be recorded from the time of signing of the informed 
consent and up to the [ADDRESS_1037583] dose of study medication  
• All subjects who remain antibody positi ve will continue to be followed for 
immunogenicity testing every [ADDRESS_1037584] returns to the clinic for an unscheduled visit (e.g., to follow -up on an abnormal 
laboratory test), the proce dures performed at this visit will be recorded in the eCRF and source 
documentation.  
6.3. Vital Signs and Physical Examinations  
A complete physical examination (review of all body systems), height, weight, and vital signs 
assessment will be performed at screeni ng. 
A complete physical examination includes a review of the following systems: head/neck/thyroid, 
eyes/ears/nose/throat, respi[INVESTIGATOR_696], cardiovascular, lymph nodes, abdomen, skin, musculoskeletal, 
and neurological. Breast, anorectal, and genital examination s will be performed when medically 
indicated. After screening, any clinically significant abnormal findings in physical examinations 
should be reported as AEs.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 59 of 81 Height and weight will be measured with shoes off. Height is to be measured using a wall 
mounted  stadiometer. When height cannot be accurately measured such as in cases of severe 
kyphosis or loss of height from vertebral compression fractures, a documented historical height 
(i.e., from government IDs, medical records, etc.) may be used.  
Vital signs i nclude orthostatic blood pressure (systolic and diastolic), temperature (oral), heart 
rate, and respi[INVESTIGATOR_697]. These will be assessed following a [ADDRESS_1037585] (seated or supi[INVESTIGATOR_050]) and 
before blood sample collection. At visits when study drug is administe red at the site, vital sign 
assessments will be collected before the dose of study drug. Supi[INVESTIGATOR_757963].  
6.4. 12-Lead Electrocardiogram  
Standard, 12-lead ECGs will be performed. A hard copy of the ECG should be printed and 
signed by [CONTACT_2057]. Any abnormalities should be noted and clinical relevance 
should be documented. An ECG will be recorded immediately prior to dosing and [ADDRESS_1037586] of study clinical 
laboratory tests is in Table  5. 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 60 of 81 Table  5: Clinical Laboratory Tests  
Hematology   Serum Chemistry Urinalysis (Dipstick)a Additional Tests 
Hemoglobin Sodium  pH PTH (1 –84)b 
Hematocrit  Potassium  Glucose  25-hydroxyvitamin Db 
1,25-dihydroxy vitamin Db 
 
WBC count with 
differential in absolute 
counts  Chloride  Protein  BSAP  
RBC count  Inorganic phosphorus  Ketones  Estradiolc 
Testosteroneb 
SHBG b 
TSH  (T3 and Free T4)c MCV  Albumin  Bilirubin  
MCHC  Total protein  Blood  
MCH  Glucose  Urobilinogen  
Platelet count  BUN  Specific gravity  
 Creatinine  Nitrite  
 Uric acid  Leukocytes  
 AST   
 ALT   
 GGT   
 CPK   
 Alkaline phosphatase   
 Total bilirubin   
 LDH   
 Total Cholesterol   
 Triglycerides   
 Total calcium   
a. Clinic only, if required by [CONTACT_976] [INVESTIGATOR_757964]  
b. Only required at Screening and Visit 8 or early termination (Month 12 visit)  
c. Only required at Screening. Reflex testing for T3 and Free T4 will be performed by [CONTACT_758007]. Reflex testing for bone -specific alkaline phosphatase will be performed by [CONTACT_758008] e normal limits.  
ALT = alanine aminotransferase; AST = Aspartate aminotransferase; BSAP = bone -specific alkaline phosphatase; 
BUN = blood urea nitrogen; CPK = Creatine phosphokinase; GGT = gamma -glutamyl transpeptidase; LDH = 
lactate dehydrogenase; MCH = m ean corpuscular hemoglobin; MCHC = mean corpuscular hemoglobin 
concentration; MCV = Mean corpuscular volume; PTH = parathyroid hormone; RBC = red blood cell; SHBG = sex 
hormone binding globulin; TSH = thyroid stimulating hormone; WBC = white blood cell  
In the event of medically significant, unexplained, or abnormal clinical laboratory test values, the 
test(s) should be repeated and followed up until the results have returned to within the normal 
range or an adequate explanation for the abnormality is found.  Clinically significant changes in 
laboratory tests that occur during the course of the study are to be reported as AEs.  
The clinical laboratory will clearly mark all laboratory test values that are outside the normal 
range and the Investigator will indica te the clinical relevance of these out -of-range values.  
6.5.2.  Serum Markers of Bone Metabolism  
Blood samples will be taken to measure efficacy related markers of bone metabolism at Day 1, 
Month 1, Month 3, Month 6, and Month 12 or early termination. S -PI[INVESTIGATOR_686] s -CTX will be 
measured in all subjects.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 61 of 81 6.5.3.  Immunogenicity Testing  
Serum samples for immunogenicity testing will be collected at Day 1 (Visit 3), Month 1 
(Visit  4), Month 3 (Visit 5), Month 6 (Visit 6), Month 9 (Visit 7), Month 12 (Visit 8), and the 
Follow -up V isit scheduled at [ADDRESS_1037587] dose of study medication  (Visit 9). Samples 
will be tested for the presence of binding anti -abaloparatide antibodies, including determination 
of antibody titer. Any positive samples will be tested for the potential to neutralize abaloparatide 
in a cell -based assay. Additionally, positive samples will be tested for cross -reactivity to 
endogenous PTH and PTHrP. Any subjects who show presence of antibodies at the Follow -up 
Visit scheduled at [ADDRESS_1037588] d ose of study medication (Visit 9) will be retested 
at 6-month intervals post -study until antibody status return to negative.  
The serum samples for immunogenicity testing will be analyzed and reported separately. All the 
planned analyses related to the immunogenicity results and antibody status will also be reported 
separately.  
6.5.4.  Pharmacokinetic Testing  
A blood sample for PK analysis of abaloparatide will be collected using a 5 mL K3 EDTA tube 
with 0.1  mg/mL aprotinin at each time point indicated in the PK  sample collection schedule 
(Table  4). 
6.5.5.  Specimen Preparation, Handling and Storage  
The procedures for the collection, handling, and shippi[INVESTIGATOR_757965] a separate Laboratory Manual provided to each clinical site.  
6.6. Imaging Procedures  
All imaging measurements (BMD according to DXA and QCT) will be performed according to 
the procedures outlined in the Imaging Charter and Imaging Manuals which will be provided as a 
separate document. A central imagin g laboratory will be utilized for all DXA and QCT readings. 
QCT will be performed in a subset of subjects at a selected number of study sites.  
6.6.1.  Dual Energy X -ray Absorptiometry  
All subjects will have areal bone density (aBMD) measurements taken via DXA of t he lumbar 
spi[INVESTIGATOR_050], total hip, femoral neck, at Screening (Visit 1), wrist at Day 1 (Visit 3); spi[INVESTIGATOR_050], total hip, 
femoral neck, and wrist at Month 3 (Visit 5), Month 6 (Visit 7), and Month 12 (Visit 8). Lumbar 
spi[INVESTIGATOR_11293] L1 through L4. Hip scans will include the entire proximal femur to 
about [ADDRESS_1037589] fractures a hip or 
forearm being examined during the study, no further scans of either hip or forearm will be 
acquired.  
For screening purposes, DXA scans of the lumbar spi[INVESTIGATOR_050], total hip, and femoral nec k taken up to 
35 days prior to the beginning of the Screening Period may be used to determine study 
eligibility. DXA scans should be performed using a study -approved scanner (and read by [CONTACT_758009]) up to [ADDRESS_1037590]’s Sc reening Visit.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-[ADDRESS_1037591] volumetric BMD (vBMD) 
measurements taken via QCT of the hip on Day 1 (Visit 3) and Month 12 (Visit 8).  
6.6.3.  Clinical and Radiologic Evaluation of Fractures  
All spi[INVESTIGATOR_757966]. All subjects will 
have X -rays taken to document fractures of the lumbar and thora cic vertebrae at Screening to 
confirm entry criteria. Radiographs of the lateral thoracic and lumbar spi[INVESTIGATOR_757967] T3 to S1. The lateral spi[INVESTIGATOR_757968] ( Genant et al, 1993 ). 
• Grade 0: Normal (approximately < 20% reduction in anterior, middle, or posterior 
height)  
• Grade 1: Mild fracture (approximately 20% –25% reduction in anterior, middle, or 
poster ior height)  
• Grade 2: Moderate fracture (approximately 25% –40% reduction in anterior, middle, 
or posterior height)  
• Grade 3: Severe fracture (> 40% reduction in anterior, middle, or posterior height)  
Incident radiological vertebral fractures occur in vertebr ae with an increase in SQ score ≥  1 at a 
Follow -up Visit. New incident radiological vertebral fractures occur in vertebrae that are not 
fractured (i.e., SQ score of 0) at Screening. Worsening incident radiological vertebral fractures 
occur in vertebrae wit h prevalent (i.e., pre -existing) fractures at baseline.  Subjects will also be 
clinically evaluated for vertebral and nonvertebral fractures (wrist, hip, rib, etc.) which occur 
during the study. Should a clinical fracture occur, X -ray images and reports ass ociated with the 
fracture must be obtained and maintained in the subject’s medical record.  
All fractures will be identified and evaluated as part of the disease assessment and will be 
documented in the case report forms and source documents.  
6.7. Discontinuatio n from the Study  
Subjects may voluntarily discontinue from the study for any reason at any time.  
Any subject who demonstrates decreases in BMD ≥  7% from baseline of this study at the lumbar 
spi[INVESTIGATOR_757958], if confirmed, will be notified by [CONTACT_3786], and be withdrawn from the study. Subjects sustaining a radiologically confirmed 
incident vertebral or nonvertebral fragility fracture will be informed of the finding and will be 
counseled as to treatment options and may discontinue or choose to remain on the study. Those 
subjects who sustain an incident frac ture during the study and elect to remain in the study will be 
asked to sign an additional informed consent document advising them of an increased risk for 
subsequent fracture.  
Subjects who decide they do not wish to participate in the study further shoul d return for the 
assessments indicated for the Month 12/Early Termination and 30 days later for the 
Month  13/Follow -up Visit in the Schedule of Assessments and Procedures ( Table  3). If they fail 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 63 of 81 to return for these assessments for unknown reasons, every effort (e.g., telephone, email, and 
letter) should be made to contact [CONTACT_476] . 
6.7.1.  Withdrawal of Consent  
Subjects may voluntarily withdraw consent to participate i n the study for any reason at any time.  
Withdrawal of consent occurs only when a subject does not want to participate in the study 
anymore and does not want any further visits or assessments and does not want any further 
study -related contact.  
If a subject  withdraws consent, the Investigator must make every effort to determine the primary 
reason for this decision and record this information. Further attempts to contact [CONTACT_758010] -up. 
6.7.2.  Early Study Termination  
The study can be terminated at any time for any reason by [CONTACT_1034]. Should this be necessary, 
subjects should be seen as soon as possible and treated as a prematurely withdrawn subject. The 
Investigator may be informed of additiona l procedures to be followed in order to ensure that 
adequate consideration is given to the protection of the subject’s interests.  
The Investigator will be responsible for informing IRBs/IECs of the early termination of the 
study.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-[ADDRESS_1037592] Operating 
Procedures (SOPs) that have been established to conform to regulatory requirements worldwide 
to ensure appropriate reporting of safety information.  
All AEs are collected from the time of the informed consent until [ADDRESS_1037593] a causal relationship with this 
treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporall y associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product ( ICH, 
1995 ). 
AEs include:  
• Worsening (change in nature, severity, or frequency) of conditions present at the 
onset of the s tudy 
• Intercurrent illnesses  
• Drug interactions  
• Events related to or possibly related to concomitant medications  
• Abnormal laboratory values (this includes significant shifts from Baseline within the 
range of normal that the Investigator considers to be clinically important)  
• Clinically significant abnormalities in physical examination, vital signs, and weight  
An abnormal laboratory value will not be assessed as an AE unless it requires a therapeutic 
intervention or is considered by [CONTACT_16426].  
7.1.2.  Serious Adverse Event  
A SAE is any AE that results in any of the following:  
• Death  
• Life-threatening: The term “life -threatening” in the definition of “serious” refers to an 
event/reaction in which the subject was at risk of death at the time of the 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 65 of 81 event/reaction; it does not refer to an event/reaction which hypothetically might have 
caused death if it were more severe.  
• Required in -subject hospi[INVESTIGATOR_1081]  
• A persistent or significant disabili ty/incapacity (i.e., substantial disruption of the 
ability to conduct normal life function)  
• Congenital anomaly/birth defect  
Important medical events that may not result in death, are life -threatening, or require 
hospi[INVESTIGATOR_212231], based upon appropriate medical judgment, they 
may jeopardize the subject and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias 
or convulsions that do not result in in -subject hospi[INVESTIGATOR_059], or the development of drug 
dependency or drug abuse.  
All AEs of osteosarcoma will be reported as SAEs. All reports of os teosarcoma, regardless of 
causality or expectedness, will be expedited to the FDA within [ADDRESS_1037594] be followed until resolution (subject has returned to baseline 
status of health) or until stabilization (the Investigator does not expect any further improvement 
or worsening of the reported event).  
7.1.3.  Recording an Adverse Event  
All AEs/SAEs will be entered into the electronic database.  
Planned hospi[INVESTIGATOR_757969] a re not to be considered AEs unless they occur at a time 
other than the planned date or the pre -existing illness or disease worsens after enrollment into the 
study.  
Fractures identified during the study are not to be recorded as AEs unless the subject is 
hospi[INVESTIGATOR_057], the fracture is complicated, or the Investigator considers the fracture to be unrelated 
to the subject’s underlying osteoporosis. All fractures will be identified and evaluated as part of 
the disease assessment and will be documented in the CRF  and by [CONTACT_758011].  
For both serious and non -serious AEs, the Investigator must determine the intensity of the event 
and the relationship of the event to study drug administration (abaloparatide and placebo). 
Intensity for each AE will be defined according to the following criteria:  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
 
 Intensity  Definition  
Mild  Awareness of sign or symptom, but easily 
tolerated.  
Moderate  Discomfort enough to cause interference 
with normal daily activities.  
Severe  Inability to perform normal daily activities.  
If the intensity of an adverse event changes within a day, the maximum intensity should be 
recorded. If the intensity changes over a longer period of time, the changes should be recorded as 
separate eve nts (having separate onset and stop dates for each intensity).  
Relationship to blinded study drug administration will be determined by [CONTACT_758012]:  
Relationship  Definition  
None  No relationship between the event and the 
administration of study drug. The event is 
related to other etiologies, such as 
concomitant medications or subject’s 
clinical state.  
Unlikely  The current state of knowledge indicates that 
a relationship to study drug is unlikely or the 
temporal re lationship is such that study drug 
would not have had any reasonable 
association with the observed event.  
Possible  A reaction that follows a plausible temporal 
sequence from administration of the study 
drug and follows a known response pattern 
to the susp ected study drug. The reaction 
might have been produced by [CONTACT_423]’s 
clinical state or other modes of therapy 
administered to the subject.  
Probable  A reaction that follows a plausible temporal 
sequence from administration of the study 
drug and follows  a known response pattern 
to the suspected study drug. The reaction 
cannot be reasonably explained by [CONTACT_202849]’s 
clinical state or other modes of therapy 
administered to the subject.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 67 of 81 For the purpose of safety analyses, all AEs that are classified with a relationship to study 
medication administration of possible or probable will be considered treatment -related events.  
[IP_ADDRESS].  Serious and Unanticipated Adverse Device Effects for Abaloparatide -SC 
An adverse device effect (ADE) is defi ned as any adverse event related to the use of an 
investigational medical device (IMD). For the purposes of this protocol, abaloparatide -SC is the 
IMD. All ADEs should be reported as an AE per Section  7.1, which includes AEs resulting from 
insufficient or inadequate instructions for use, deployment, implantation, installation, operation, 
any malfunction of the IMD, use error, or intentional misuse of the  IMD (ISO/DIS [ZIP_CODE]).  
An unanticipated adverse device effect (UADE) is defined as any serious adverse effect on 
health or safety or any life -threatening problem or death caused by, or associated with, the 
abaloparatide -SC device, if that effect, problem, o r death was not previously identified in nature, 
severity, or degree of incidence in the application/IB, or any other unanticipated serious problem 
associated with a device that relates to the rights, safety, or welfare of subjects (21 CFR 
812.3(s)).  
Any U ADE that occurs during the study from the time the subject signs the ICF until [ADDRESS_1037595] awareness of the 
event using the SAE and the UADE report forms and emailing to [EMAIL_14484] . 
The Investigator and the Sponsor will immediately conduct an evaluation of any UADE 
occurring with abaloparatide -SC. The results of the evaluation will be reported to the IRB within 
[ADDRESS_1037596] awareness of the event 
using the SAE report form and emailing to [EMAIL_14484]. Data should also be entered 
in the clinical trial eCRF.  
Treatment -related SAEs will be followed until resolution or stabilization. The reference safety 
information for this study is the IB, which will be provided under separate cover to all 
Investigators.  
Any SAEs that occur at any time after completion of the study, which the Investigator considers 
to be related to study drug, must be re ported to the Sponsor or its designee.  
The Investigator must submit the SAE to the IRB/ IEC in accordance with [ADDRESS_1037597]. In order to fulfill regulatory reporting 
obligations worldwide, the Investigator is responsible for the detection and documentation of 
events meeting the definition of a UADE that occ urs with abaloparatide -SC (Section  [IP_ADDRESS] ). 
Any UADEs that occur during the study with abaloparatide -SC, from the time the subject signs 
the ICF until  [ADDRESS_1037598] to follow -up. 
SAEs (initial reports and follow -up information) must be reported by [CONTACT_758013]; the form must be completed and emailed t o [EMAIL_14484].  
The Investigator will comply with the applicable local regulatory requirements relating to 
reporting to the IRB/IEC.  
7.1.6.  Follow -up of Adverse Events  
All treatment -related AEs will be followed with appropriate medical management until reso lved 
or stabilized.  
UADEs will be followed until their medical outcome is determined, with periodic written reports 
about the status provided to the Sponsor.  
7.1.7.  Abuse, Misuse, Overdose, or Medication Error  
Abuse, misuse, overdose, or medication error (as defi ned below) must be reported to the Sponsor 
whether or not they result in an AE/ SAE.  
• Abuse – Persistent or sporadic intentional intake of investigational medicinal product 
at a dose higher than prescribed per protocol (but below the dose defined for 
overdos e) or when used for non -medical purpose (e.g., altering one’s state of 
consciousness).  
• Misuse – Intentional or unintentional use of investigational medicinal product other 
than as directed or indicated at any dose, which is at or below the dose defined for  
overdose Note: this includes a situation where the test article is not used as directed at 
the dose prescribed by [CONTACT_760].  
• Overdose – Intentional or unintentional injection of a dose of abaloparatide at least 
2 times higher than the protocol -specifie d dose and is associated with clinical 
symptoms.  
• Medication Error – A mistake made in prescribing, dispensing, administration and/or 
use of the investigational medicinal product.  
7.1.8.  Pregnancy  
Any pregnancy for the partner of a study participant must be report ed on the Partner’s Pregnancy 
Report Form within 24 hours and email ed to the R ADIUS  Pharmacovigilance Department at 
[EMAIL_14484]. Every effort should be made to gather information regarding the 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-[ADDRESS_1037599] and his partner should abstain 
from sexual interco urse, or use highly effective contraceptive measures (e.g., oral contraceptive 
and condom, IUD and condom, or diaphragm with spermicide and condoms; other forms of 
contraception must be approved by a Medical Monitor) when engaging in sexual intercourse 
throughout the study, and for at least [ADDRESS_1037600], Ethics Committee and Site 
Reporting  
The Sponsor and/or the clinical contract research organization (CRO) are responsible for 
notifying the relevant regulatory authorities/US central IRBs/EU central IEC committees of 
related, unexpected SAEs.  
The Investigator is responsible for notifying the Sponsor, CRO, and local IRB/IEC, or the 
relevant local regulatory authority of all SAEs tha t occur at his or her site as required.  
If a death occurs during the study or within 30 days after Month 12/Early Termination visit 
(Visit  8), and it is determined to be related either to a study procedure or a study drug, the 
Investigator or his/her designee must notify the Sponsor and will communicate that information 
to the IRB/IEC within one business day of knowledge of the event. The contact [CONTACT_758014].  
7.2. Study Completion and Post -Study Treatment  
The Investigator must provide follow -up medical care for all subjects who are prematurely 
withdrawn from the study due to an adverse event or must refer them for appropriate ongoing 
care.  
7.3. Lost to Follow -up 
For subjects whose status is unclear because they fail to appear for study visits without  stating an 
intention to discontinue or withdraw, the Investigator should show "due diligence" by 
[CONTACT_762], e.g., dates of telephone 
calls, registered letters. A subject should not be formally c onsidered lost to follow -up until 
multiple attempts to contact [CONTACT_394012], including at least [ADDRESS_1037601]’s last known mailing 
address.  
 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 70 of 81 8. STATISTICAL CONSIDER ATIONS  
8.1. Statistical and Analytical Plans  
A comprehensive SAP will be completed and approved prior to database lock. All statistical tests 
will be 2 -sided with a significance level of 1%, unless otherwise specified.  
8.2. Statistical Hypotheses  
The primary objective  of this study is to evaluate the efficacy and safety of abaloparatide -SC 
80 µg per day compared to placebo in men with osteoporosis. The hypotheses to be tested are 
that abaloparatide is superior to placebo, and that the safety profile of abaloparatide -SC in 
osteoporotic men is similar to that of abaloparatide -SC in postmenopausal women with 
osteoporosis.  
8.3. Analysis Datasets  
8.3.1.  Populations for Analysis  
The primary population for all efficacy analyses will be the Intention -to-Treat (ITT) Population , 
which is def ined as all subjects randomized into this study . The primary population for safety 
analyses will be the Safety Population, defined as all subjects who received at least one dose of 
study medication. The Per -Protocol (PP) Population will include all ITT sub jects who did not 
have any significant protocol deviations and will be used for supportive analyses. The criteria for 
the exclusion from the PP Population will be appropriately documented prior to database lock 
and treatment unblinding.   
8.4. Description of Sta tistical Methods  
8.4.1.  General Approach  
Analyses will be presented by [CONTACT_1570] (abaloparatide -SC and placebo) and overall, when 
appropriate. Baseline is defined as the last value obtained prior to the first dose of study 
medication.  
For categorical data, summary tabulations of the number and percentage of subjects within each 
category of the parameter will be presented. For continuous data, the number of subjects, mean, 
median, standard deviation (SD), minimum, interquartile range (Q1 and Q3), and maximum will 
be presented.  
8.4.2.  Analysis of the Primary Efficacy Endpoint(s)  
The primary efficacy endpoint will be the percent change in lumbar spi[INVESTIGATOR_757970] 
[ADDRESS_1037602] data from subjects who 
discontinue treatment early, the “retrieved dropouts” approach for handling m issing data is not 
applicable for this study. To appropriately address the possibility of data missing not at random, 
the primary analysis will be based on a pattern -mixture model (PMM) analysis with multiple 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-[ADDRESS_1037603]’s discontinuation 
from the study. The missing primary endpoint values for subjects in the abaloparatide -SC group 
will be imputed with the observed baseline and data from the placebo group ; no intermediate 
values from the abaloparatide -SC group  will be used in the imputation for the abaloparatide -SC 
group. For subjects in the placebo group, intermediate observed values from the completers in 
the placebo group  will be used while imputing missing values during the 12 -month Treatment 
Period . The PROC MI methodology for imputation of monotone missing data patterns will be 
used to impute the outcome variables at consecutive visits in a sequential ( chain) manner. Each 
of these imputed datasets will be analyzed using analysis of covariance (ANCOVA) with 
treatment and DXA instrument manufacturer as fixed effects and the baseline lumbar spi[INVESTIGATOR_757971] a covariate. Results from all imputed datasets will be  combined using PROC MIANALYZE 
for overall statistical inference. The statistical tests will be 2 -sided comparing abaloparatide -SC 
to placebo; 99% CIs will be presented together with the estimated p -values.   
As a sensitivity analysis, the primary efficacy endpoint will also be analyzed using a Mixed 
Model for Repeated Measures (MMRM) analysis. The MMRM model will include the fixed 
effects of treatment, DXA instrument manufacturer, visit, and treatment -by-visit interaction, with 
the baseline lumbar spi[INVESTIGATOR_757972] a covariate. For the MMRM model, an unstructured variance -
covariance matrix shared between the [ADDRESS_1037604] 
(differ ence in least squares mean) between the 2 treatment groups at Month 12 (Visit 8). The 
statistical tests will be 2 -sided comparing abaloparatide -SC to placebo; 99% CIs will be 
presented together with the estimated p -values.  
Sensitivity analyses for addressi ng the effect of the COVID -[ADDRESS_1037605] (LOCF) method to impute missing data will 
also be conducted.   
8.4.3.  Analysis of Secondary Endpoint(s)  
The key secondary efficacy endpoints are:  
• Percent chan ge from baseline in total hip BMD at 12 months  
• Percent change from baseline in femoral neck BMD at 12 months  
Additional secondary efficacy endpoints are:  
• Percent change from baseline in : 
− Lumbar spi[INVESTIGATOR_531859] 3 and 6 months  
− Total hip BMD at 3 and 6 months  
− Femoral neck BMD at 3 and 6 months  
− Ultra -distal radius BMD at 3, 6, and 12 months  
− Distal one -third radius BMD at 3, 6, and 12 months  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 72 of 81 • Log ratio of post -baseline over baseline in : 
− s-PI[INVESTIGATOR_757973] 1, 3, 6, and 12 months  
− s-CTX at 1, 3, 6, and 12 months  
• Proportion of  subjects experiencing BMD gains from baseline of >  0%, >  3%, and 
> 6% at the lumbar spi[INVESTIGATOR_050], femoral neck, and total hip at 3, 6, and 12 months  
• Incidence of new clinical fractures at 12 months  
• Proportion of subjects converting from the categories of osteoporosis to osteopenia or 
to normal at 12 months, where:  
− Osteoporosis is defined as lumbar spi[INVESTIGATOR_757952] T -score ≤ -2.5.  
− Osteopenia is defined as one of the following:  
o Lumbar spi[INVESTIGATOR_050] > -2.5 and total hip BMD T -score > -2.5 and < -1.0 
o Lumbar spi[INVESTIGATOR_050] > -2.5 and < -1.0 and total hip BMD T -score > -2.5  
− Normal is defined as lumbar spi[INVESTIGATOR_757953] T -score ≥ -1.0.  
• The percent change in total hip and femoral neck volumetric BMD as measured  by 
[CONTACT_758015] [ADDRESS_1037606] will be performed in a subset of subjects at a 
selected number of study sites . 
Analyses of the primary and key secondary endpoints will follow a fixed -sequence testing 
approach to control the overall Type 1 error rat e at the 2 -sided significance level of 1%. To claim 
statistical significance at the 2 -sided level of 1%, the following 3 fixed -sequence tests will be 
performed in sequential order. At any step of the sequential testing, if the treatment difference is 
not s tatistically significant at the 1% level then all the subsequent comparisons following the 
fixed sequence cannot be claimed statistically significant.  
1. Percent change from baseline in BMD at the lumbar spi[INVESTIGATOR_16717] [ADDRESS_1037607] -baseline BMD values. Three categories of BMD response will be 
evaluated: %BMD increase >  0%, >  3%, and >  6%. The response will be assessed at the lumbar 
spi[INVESTIGATOR_050], total hip, and femoral neck . Subjects who have BMD increase at all [ADDRESS_1037608] or Fisher’s exact test.  
Kaplan -Meier estimates for the time to new clinical fracture at [ADDRESS_1037609] ratio 
(99% CI) will be presented, with treatment comparisons based on the log -rank tes t. 
The number and percentage of subjects for whom disease status (categories as defined in the 
secondary endpoints listed earlier in this section ) has changed from osteoporosis at baseline to 
osteopenia, normal, or no change at [ADDRESS_1037610].  
The percent change from baseline in total hip and femoral neck volumetric BMD (vBMD) at 
[ADDRESS_1037611] will be analyzed using a similar ANCOVA model as 
stated in Section  8.4.2 . 
The primary analyses of the secondary efficacy variables will be based on the ITT Population  
and will be repeated using the PP Population . 
Subgroup analysis (e.g., age, geograph y, FRAX, prior fracture, and baseline BMD, s -PI[INVESTIGATOR_680], 
testosterone, and estradiol levels) may be performed. Details of the subgroup analyses will be 
described in the SAP.  
8.4.4.  Pharmacokinetic Analyses  
A population PK analysis will be performed on the sparse plasma  concentration data of 
abaloparatide as described in the Pharmacometric Analysis Plan. This analysis may be expanded 
to include a population PK/exposure -response analysis of the percent change in BMD from 
baseline over time.  
8.4.5.  Safety Analyses  
Unless otherwis e specified, safety analyses will be conducted using the Safety Population and 
will be descriptive in nature.  
Study drug exposure and study drug compliance will be calculated. The duration of study drug 
exposure, total dose received, and percent compliance  will be summarized by [CONTACT_1570].  
All AEs will be coded using MedDRA. The number and percent of subjects who experienced 
TEAEs will be summarized by [CONTACT_11189] (SOC), preferred term, and 
treatment group. Summaries will also be provided  for severe TEAEs, SAEs, TEAEs leading to 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 74 of 81 study drug withdrawal, drug -related TEAEs (with probable or possible relationship to study 
drug), and TEAEs by [CONTACT_764] (mild, moderate, severe).  
The number and percent of subjects who report TEAEs associat ed with hypercalcemia and 
hypercalciuria will be summarized by [CONTACT_1570].  
All AEs collected prior to the first dose of study drug will be summarized separately.  
A listing of subjects who experience an UADE will be provided.  
Descriptive statistics for  laboratory data (including serum calcium and albumin), vital signs 
(including orthostatic blood pressure [BP]), ECGs, Investigator assessment of local tolerance, 
and subject assessment of local tolerance will be provided by [CONTACT_6982]. For 
laboratory data, vital signs, and ECGs, absolute results and changes from baseline will be 
presented. In addition, laboratory test results will be classified as above normal limit, within 
normal limit, or below normal limit. Laboratory shift frequencies wi ll be tabulated between the 
Screening Visit and relevant post -baseline visit(s).  
For subjects in the abaloparatide -SC group, the anti -abaloparatide antibody assessment in the 
serum samples for immunogenicity testing will be categorized by 2 outcomes:  
• Negat ive for anti -abaloparatide antibodies  
• Positive for anti -abaloparatide antibodies  
The number (%) of subjects in the above categories of abaloparatide antibodies will be 
summarized on Day 1 (Visit 3)  and at Month 1 (Visit 4), Month 3 (Visit 5), Month 6 (Visi t 6), 
Month 9 (Visit 7), Month 12 (Visit 8) , and the Follow -up Visit scheduled approximately [ADDRESS_1037612] dose of study medication (Visit 9) using the Antibody Population.  
For those subjects with a positive anti -abaloparatide antibody present, t he titer level, presence of 
neutralizing anti -abaloparatide antibodies (negative or positive), and  assessment outcomes for 
cross -reactivity to PTH (negative or positive) and PTHrP antibodies (negative or positive) , 
together with the neutralizing antibody s tatus in subjects that are positive for PTH (negative or 
positive for the presence of PTH -neutralizing antibodies) or PTHrP (negative or positive for the 
presence of PTHrP -neutralizing antibodies) , will be summarized by [CONTACT_15449].  
The results of antibod y analyses will be included in a separate report.  
Concomitant medications will be coded using the World Health Organization (WHO) Drug 
Dictionary and summarized by [CONTACT_758016] p. 
8.4.6.  Adherence and Retention Analyses  
The number and percentage of subjects who withdraw from the study, with primary reason , will 
be summarized by [CONTACT_1570].  
8.4.7.  Baseline Descriptive Statistics  
Medical history, physical examination, demographics, and baseline characteristics will be 
summarized and presented by [CONTACT_6654]. Medical history will be presented by 
[CONTACT_55366], summarizing the proportion of subjects who have a con dition noted. 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 75 of 81 Results from the baseline physical examination will be summarized by [CONTACT_758017].  
8.4.8.  Interim Analyses  
There are no interim analyses planned for this study.  
8.4.9.  Additional Subgroup Analyses  
Subgroup analysis (e.g., age, geog raphy, FRAX (if applicable), prior fracture, and baseline 
BMD, s -PI[INVESTIGATOR_680], testosterone, and estradiol levels) may be performed and will be described in the 
SAP.  
8.4.10.  Multiple Comparison/Multiplicity  
As stated in Section  8.4.3 , a fixed -sequence testing approach will be employed to control the 
Type 1 error rate at the 2 -sided significance level of 1% for testing the primary and secondary 
efficacy endpoints. No ot her adjustments for multiple comparisons will be made.  
8.4.11.  Tabulation of Individual Response Data  
Individual efficacy, PK, and safety data will be tabulated as appropriate.  
8.4.12.  Exploratory Analyses  
Prespecified exploratory variables and analyses are described in S ection  8.4.3 . 
8.5. Sample Size Calculation  
A study sample size of 225 subjects (150 in the abaloparatide -SC group and 75 in the placebo 
group) will provide at least 99% power to detect a mean difference of 6.5%  in the percentage 
change from baseline in lumbar spi[INVESTIGATOR_531859] 12 months between the abaloparatide -SC and the 
placebo groups at a 2 -sided alpha level of 0.01, assuming a SD of 6.0% and a drop -out rate of 
10%. For the key secondary endpoints, this total sam ple size of [ADDRESS_1037613] 96% 
power to detect a 2.2% mean difference (SD = 3.5%) of percent change in total hip BMD at 
12 months, and 80% power to detect a 2.0% mean difference (SD = 4.1%) of percent change in 
femoral neck BMD at 12 months.  
8.6. Measur es to Minimize Bias  
Not applicable.  
8.7. Enrollment/Randomization/Masking Procedures  
Abaloparatide -SC and placebo study medications will be prepared in a blinded fashion. Data will 
be reviewed in a blinded fashion and the analysis populations defined prior to d atabase lock and 
unblinding.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 76 of 81 9. ADMINISTRATIVE REQUI REMENTS  
9.1. Ethical Considerations  
This clinical study will be conducted in accordance with the current version of the ICH 
Harmonized Guideline for Good Clinical Practice (GCP), with applicable local laws and 
regulations, and with the ethical principles laid down in the Declaration of Helsinki.  
The Investigator will ensure that this study is conducted in full conformity with ICH GCP 
E6(R2).  
The IRB/IEC will review all appropriate study documentation to safeguard the rights, safety, and 
well-being of the subjects. The study will only be conducted at sites where IRB/IEC approval has 
been obtained. The protocol, IB, ICF, advertisements (if applicable), written information given to 
the subjects, safety updates, annual  progress reports, and any revisions to these documents will 
be provided to the IRB/IEC by [CONTACT_648813], as allowable by [CONTACT_168802].  
9.2. Subject Information and Informed Consent  
The Investigator is responsib le for obtaining written, informed consent from each subject 
interested in participating in this study before conducting any study -related procedures.  
Written informed consent should be obtained after adequate, thorough, and clear explanation of 
the study objectives, procedures, as well as the potential hazards of the study. The method of 
obtaining and documenting the informed consent and the contents of the consent will comply 
with ICH  GCP and all applicable laws and regulations and will be subject to appr oval by 
[CONTACT_770].  
9.3. Investigator Compliance  
No modifications to the protocol should be made without the approval of both the Investigator 
and RADIUS. Changes that significantly affect the safety of the subjects, the scope of the 
investigation, or the scientific quality of the study (i.e.,  efficacy assessments) will require 
IRB/IEC notification before implementation, except where the modification is necessary to 
eliminate an apparent immediate hazard to human subjects. RADIUS will submit all prot ocol 
modifications to the required regulatory authorities.  
When circumstances require an immediate departure from procedures set forth in the protocol, 
the Investigator will contact [CONTACT_758018]. If possible, contact 
[CONTACT_772]. Any departures from protocol must 
be fully documented in the source documentation.  
9.4. Access to Records  
The Investigator must make the office and/or hospi[INVESTIGATOR_757974], audit by [CONTACT_758019] (QA) and inspection by [CONTACT_397149]. The records must also be 
available for inspection, verification, and copying, as required by [CONTACT_758020], by [CONTACT_775] (FDA and others). The Investigator 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-[ADDRESS_1037614] numbers. As required by [CONTACT_17926], the 
Investigator will allow RADI US and/or its representatives access to all pertinent medical records 
to allow for the verification of data gathered in the eCRFs/SAE Forms and the review of the data 
collection process. The FDA (or other regulatory authority) may also request access to al l study 
records, including source documentation, for inspection.  
As applicable, in accordance with the Health Insurance Portability and Accountability Act 
(HIPAA) and associated privacy regulations, a subject authorization to use personally 
identifiable he alth information may be required from each subject before research activities 
begin.  
Subject confidentiality is strictly held in trust by [CONTACT_778], their staff, and 
RADIUS and their representatives. This confidentiality is extended t o cover testing of biological 
samples and genetic tests in addition to the clinical information relating to participants. 
Therefore, the study protocol, documentation, data, and all other information generated will be 
held in strict confidence. No informat ion concerning the study or the data will be released to any 
unauthorized third party without prior written approval of RADIUS.  
9.6. Research Use of Stored Human Samples, Specimens, or Data  
With the subject’s approval, and as approved by [CONTACT_779]’s IRB/IEC, bio logical samples may be 
stored at a centralized facility determined by [CONTACT_780]. These samples could be used for 
retrospective biomarker research or analysis of clinical response to therapy and to improve 
current and future treatment outcomes. The storage fac ility will maintain the masking of the 
identity of the subject.  
During the conduct of the study, any individual subject can choose to withdraw consent to have 
biological specimens stored for future research. When the study is completed, access to study 
data and/or samples will be provided through RADIUS.  
9.7. Data Quality Assurance  
RADIUS or its designated representative will conduct a study site visit to verify the 
qualifications of each Investigator, inspect clinical study site facilities as needed, and inform  the 
Investigator of responsibilities and procedures for ensuring adequate and correct study 
documentation.  
The Investigator is required to prepare and maintain adequate and accurate case histories 
designed to record all observations and other data pertine nt to the study for each study subject. 
Study data for each enrolled subject will be entered into an eCRF by [CONTACT_781] a 
secure, validated web -based electronic data capture (EDC) application. RADIUS will have read -
only access to all data upon en try in the EDC application.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-[ADDRESS_1037615] a regulatory inspection of this 
study. Such audits/inspections can occur at a ny time during or after completion of the study. If an 
audit or inspection occurs, the Investigator and institution agree to allow the auditor/inspector 
direct access to all relevant documents and to allocate his/her time and the time of his/her staff to 
the auditor/inspector to discuss findings and any relevant issues. In the case of an audit or 
inspection, the Investigator or a delegate will alert RADIUS, as soon as he/she becomes aware of 
the audit or inspection.  
The Investigator and study staff are resp onsible for maintaining a comprehensive and accurate 
filing system of all study -related documentation that will be suitable for inspection at any time 
by [CONTACT_780], its designees, and/or regulatory agencies. In signing this protocol, the Investigator 
understa nds and agrees to give access to the necessary documentation and files.  
9.8. Monitoring  
RADIUS is responsible for ensuring the proper conduct of the study with regard to protocol 
adherence and validity of data recorded in the clinical database. The study will b e monitored by 
[CONTACT_770]. Monitoring will be done by [CONTACT_782] a representative of 
RADIUS, or designee (site monitor), who will review the eCRFs, SAE Forms and source 
documents. The site monitor will ensure that the investigation is  conducted according to the 
protocol design and regulatory requirements.  
9.9. Data Collection and Management Responsibilities  
Data collection is the responsibility of the clinical study staff at the site under the supervision of 
the Investigator. The Investigator is responsible for ensuring the accuracy, completeness, 
legibility, and timeliness of the data reported.  
RADIUS will provide the study sites with secure access to and training on the EDC application 
sufficient to permit site personnel to enter  and correct information in the eCRFs on the subjects 
for which they are responsible for.  
An eCRF will be completed for each subject who receives at least one dose of study drug.  It is 
the Investigator's responsibility to ensure the accuracy, completeness , clarity, and timeliness of 
the data reported in the subject’s eCRF.  Source documentation supporting the eCRF data should 
indicate the subject’s participation in the study and should document the dates and details of 
study procedures, AEs, other observati ons, and subject status.  
The Investigator, or designated representative, should complete the eCRF in a timely manner 
after information is collected.  
The audit trail entry will show the user's identification information and the date and time of any 
correcti on. The Investigator must provide formal approval of all the information in the eCRFs, 
including any changes made to the eCRFs, to endorse the final submitted data for the subjects for 
whom the Investigator is responsible.  
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-[ADDRESS_1037616] disc or other electronic media will be provided to the site 
for placement in the Investigator's study file.  
9.10. Study Records Retention  
The Investigator will ma intain study documents for a minimum of [ADDRESS_1037617] be notified. No records will be 
destroyed without the written consent of RADIUS.  
9.11. Publication and Data Sharing Policy  
Publication of complete data from the study is planned. It is anticipated that the results of this 
study will be presented at scientific meetings and/or published in a peer reviewed scientific or 
medical journal. A Publications Committee composed of Investigators participating in the study 
and repre sentatives from RADIUS as appropriate will be formed to oversee the publication of the 
study results, which will reflect the experience of all participating study sites.  
Subsequently, individual Investigators may publish results from the study in compliance with 
their agreement with RADIUS.  
 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 80 of 81 10. LITERATURE REFERENCE S 
Bilezikian JP. Anabolic therapy for osteoporosis. Women’s Health (Lond). 2007;3:243 -253. 
Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid 
hormone on bo ne. Endocr Rev. 1993;14:690 –709. 
Ebeling PR. Osteoporosis in men. New Engl J Med. 2008;358:1474 -1482.  
Food and Drug Administration (FDA). FDA Guidance on Conduct of Clinical Trials of Medical 
Products During the COVID -19 Public Health Emergency. 2021; acce ssed via 
https://www.fda.gov/media/136238/download  
Genant HK, Wu CY, van Kuijk KC, Nevitt MC. Vertebral fracture assessment using a 
semiquantitative technique. J Bone Miner Res. 1993;8:1137 -1148.  
Hattersley G, Dean T, Corbin BA., Bahar H, Gardella TJ. Bind ing selectivity of abaloparatide for 
PTH -type-1-receptor conformations and effects on downstream signaling. Endocrinology. 
2016;157:141 -49. 
International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Us e (ICH)  Guideline for Industry - Clinical Safety Data 
Management: Definitions and Standards for Expedited Reporting (ICH E2A). 1995  
International Organization of Standardizations. (2018). Clinical investigation of medical devices 
for human subjects — Good clinical practice, ISO/DIS [ZIP_CODE]. 
https://www.iso.org/obp/ui/#iso:std:iso:[ZIP_CODE]:dis:ed -3:v1:e n. Accessed 11 -Nov-2019  
International Osteoporosis Foundation. Osteoporosis in me n. 2014; accessed via 
http://www.iofbonehealth.org/WOD/2014/thematic -report/WOD14 -Report.pdf  
Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocrine Rev. 2008;29:441 -464. 
Litwic A, Lekarz, Warwick D, Denniston E. Distal radius fracture: Cinderella of the osteoporotic 
fractures. Orthop Muscul Syst. 2014; 3:162 -8. 
Makino M, Takagi H, Sugiyama H, Kobayashi T, Kasahara Y. Effects of abaloparatide on the 
expression of bone resorption and formation -related factors in osteoblastic cells; a comparison 
with ter iparatide. Annual Meeting of the American Society for Bone and Mineral Research 2015; 
MO0121.  
Mannstadt M, Juppner H, Gardella TJ. Receptors for PTH and PTHrP: Their biological 
importance and functional properties. Am J Physiol. 1999; 277:F665 -F675  
Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, 
Hu M, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C. Effect of abaloparatide vs placebo 
on new vertebral fractures in postmenopausal women with osteoporosis: a rando mized clinical 
trial. J Am Med Assoc. 2016;316:722 -733. 
Newcombe RG. Interval estimation for the difference between independent proportions: 
Comparison of eleven methods. Stat Med. 1998; 17:873 -890. 
Rizzoli R. Osteoporosis, genetics and hormones. J Mol End ocrinol. 2001;26:79 -94. 
Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2005;353:595 -603. 
Radius Health, Inc.  
Abaloparatide -SC  Confidential  
Study BA058 -05-019 Amendment 6   Page 81 of 81 WHO. Assessment of osteoporosis at the primary health care level. Summary of a WHO  
Scientific Group 2007 [16 Feb 2017]. Available from: 
www.wh o.int/chp/topi[INVESTIGATOR_1102]/rhuematicrheumatic/en/index.html  
Signature [CONTACT_793]-CLIN-000847 v8.0
Signature [CONTACT_793]-CLIN-000847 v8.0Approval
31-Mar-2021 13:36:14 GMT[PHONE_006]
Approval
31-Mar-2021 13:50:41 GMT[PHONE_006]
Approval
31-Mar-2021 15:57:03 GMT[PHONE_006]
Approval
31-Mar-2021 22:38:39 GMT[PHONE_006]
